



US 2010055722A1

(19) **United States**

(12) **Patent Application Publication**
Nayak et al.

(10) **Pub. No.: US 2010/0055722 A1**
(43) **Pub. Date: Mar. 4, 2010**

(54) **METHODS OF DETECTING A
NEUROLOGICAL CONDITION VIA
ANALYSIS OF CIRCULATING PHAGOCYTES**

61/020,820, filed on Jan. 14, 2008, provisional appli-
cation No. 61/042,407, filed on Apr. 4, 2008.

Publication Classification

(76) Inventors: **Ramesh C. Nayak**, Tucson, AZ
(US); **Marie Wesselhoft**, Vail, AZ
(US)

(51) **Int. Cl.**
G01N 33/53 (2006.01)
C12Q 1/02 (2006.01)
C12Q 1/48 (2006.01)
C12Q 1/32 (2006.01)

Correspondence Address:
Nguyen & Tarbet
6039 E. Grant Rd.
Tucson, AZ 85712 (US)

(52) **U.S. Cl. 435/7.92; 435/29; 435/15; 435/26;**
435/7.1

(21) Appl. No.: **12/325,035**

(57) **ABSTRACT**

(22) Filed: **Nov. 28, 2008**

Related U.S. Application Data

(60) Provisional application No. 60/991,594, filed on Nov.
30, 2007, provisional application No. 61/007,728,
filed on Dec. 14, 2007, provisional application No.

The present invention features methods of monitoring or
detecting a neurological or inflammatory condition in a
patient. The method comprises (1) obtaining from the patient
a fluid sample from outside of a brain tissue of the patient,
wherein the fluid sample contains a circulating phagocyte,
and (2) detecting for one or more biomarkers (e.g., a panel of
biomarkers) inside the phagocyte, wherein the biomarker is
associated with the respective neurological or inflammatory
condition.

**METHODS OF DETECTING A
NEUROLOGICAL CONDITION VIA
ANALYSIS OF CIRCULATING PHAGOCYTES**

CROSS REFERENCE

[0001] This application claims priority to U.S. provisional application Ser. No. 60/991,594 filed Nov. 30, 2007; U.S. provisional application Ser. No. 61/007,728 filed Dec. 14, 2007; U.S. provisional application Ser. No. 61/020,820 filed Jan. 14, 2008; U.S. provisional application Ser. No. 61/042,407 filed Apr. 4, 2008; the entire disclosures of which are incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

[0002] Multiple Sclerosis (MS) is predominantly a disease of women of northern European origin and afflicts up to three million people worldwide. In the United States it is estimated that 400,000 people are affected. It is thought to be an autoimmune disorder and typically strikes young adults, causing a wide variety of symptoms that are often mistaken for other diseases. These symptoms stem from disruption of the central nervous system (CNS) and may include blurred or double vision; weakness in the arms or legs; changes or difficulties in balance, coordination and gait; bladder and/or bowel dysfunction; and emotional disturbances. Each patient may present a little differently and there may have been episodes in the past which were barely noticed by the patient at the time. It is difficult to firmly diagnose MS, especially if there has been only one symptomatic episode. This leaves patients and their doctors waiting months or years for a relapse to confirm that the symptoms are due to MS.

[0003] MS is a demyelinating disease, where myelin, the insulating layer on nerve fibers, is destroyed in the CNS, which consists of the brain, optic nerves, and spinal column. There is an accompanying inflammatory response and the blood brain barrier (BBB) is breached. Axon damage can occur and the optic nerve is commonly affected. Myelin damage makes it more difficult for nerves to transmit impulses, leading to symptoms of MS. The diagnostic McDonald Criteria (1) were revised in 2005 to include magnetic resonance imaging (MRI) criteria of different types of lesions of the brain and spinal cord in the diagnosis of MS. Prognosis is difficult to determine, and many brain lesions do not necessarily correlate with severity of disease. There are medications available to alleviate some symptoms and a few others to modify and hopefully delay the onset or severity of relapses of MS.

[0004] The most common form of MS is relapsing-remitting multiple sclerosis (RRMS), which is characterized by symptomatic episodes separated in time, with partial or complete recovery of an apparently normal state between relapses. It often converts to secondary progressive MS after several years, where there is a steady worsening of symptoms. A minority of patients have Primary Progressive MS which presents as a continuous slow worsening of the disease state. An even smaller minority of patients is diagnosed with Progressive-Relapsing MS, where in contrast to RRMS, there is a continuous worsening of their condition between acute episodes. A first episode is referred to as Clinically Isolated Syndrome (CIS) pending a more certain diagnosis of MS corresponding to clinical signs and/or brain lesions visualized by MRI, or possibly a spinal tap to check for immunoglobulin oligoclonal bands (OCB) in the cerebral spinal fluid (CSF).

None of these diagnostic methods is 100% specific. (2). Its drawbacks include the expense and the fact that a patient must wait one to three months between scans to determine if new lesions have formed during the intervening period. There is a clear need for identification of a biomarker or set of biomarkers that indicate presence and/or severity of disease for MS patients. A simple blood test would be ideal for diagnosing MS, however at this time, no commercial blood test exists.

[0005] Early diagnosis of MS is thought to be increasingly important, as much of the damage occurs early in the disease process. The earlier the diagnosis, the earlier disease-modifying treatment can begin and progression of the disease and associated disability can hopefully be slowed.

[0006] The present invention features a method of detecting multiple sclerosis or a risk of multiple sclerosis. The method comprises detecting a multiple sclerosis-associated biomarker, e.g., an antigen, wherein detecting an elevated level of such multiple sclerosis-associated biomarker indicates the presence of multiple sclerosis or a risk of multiple sclerosis.

SUMMARY OF THE INVENTION

[0007] The present invention features a method of monitoring or detecting a neurological condition in a patient, the method comprises (a) obtaining from a patient a fluid sample from outside of a brain tissue of the patient, the fluid sample contains a circulating phagocyte; and (b) detecting a biomarker associated with the neurological condition in the phagocyte.

[0008] Further, the present invention features a method of monitoring or detecting multiple sclerosis (or a risk of multiple sclerosis) in a patient, the method comprises (a) obtaining from the patient a fluid sample from outside of a brain tissue of the patient, the fluid sample contains a circulating phagocyte; and (b) detecting a multiple sclerosis-associated biomarker in the phagocyte.

[0009] Still further, the present invention features a method of monitoring or detecting an inflammatory condition in a patient, said method comprising (a) obtaining from the patient a fluid sample from outside of a brain tissue of the patient, the fluid sample contains a circulating phagocyte; and (b) detecting a biomarker in the phagocyte, wherein the biomarker is associated with the inflammatory condition.

[0010] In some embodiments, the monitoring of one of the above conditions is achieved by detecting the level of the respective biomarkers through a time interval. In some embodiments, a decrease in the level of a biomarker through time is an indication that the condition is improving (assuming that the level of biomarker directly correlates with the severity of the condition). In some embodiments, an increased in the level of a biomarker through time is an indication that the condition is improving (assuming that the level of biomarker is inversely correlates with the severity of the condition).

[0011] In some embodiments, the detection of the one of the above conditions is achieved by detecting a biomarker that is at a level that is higher than that of a control (assuming that an elevated level of the biomarker relative to that of a control is indicative of a condition—this correlation may be established by routine procedures by one of ordinary skill).

[0012] In some embodiments, the detection of the one of the above conditions is achieved by detecting a biomarker that is at a level that is lower than that of a control (assuming that a decreased level of the biomarker relative to that of a control

is indicative of a condition—this correlation may be established by routine procedures by one of ordinary skill).

[0013] Any feature or combination of features described herein are included within the scope of the present invention provided that the features included in any such combination are not mutually inconsistent as will be apparent from the context, this specification, and the knowledge of one of ordinary skill in the art. Additional advantages and aspects of the present invention are apparent in the following detailed description and claims. Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in the present application is incorporated herein by reference in its entirety.

DESCRIPTION OF PREFERRED EMBODIMENTS

Inflammatory Conditions

[0014] The present invention features a method of detecting an inflammatory condition. The method comprises obtaining from a patient a fluid sample that contains a peripheral (e.g., circulating) phagocyte, and detecting one or more biomarker, e.g., an antigen, inside a phagocyte of said fluid sample, wherein the biomarker is associated with an inflammatory condition. The fluid obtained does not directly come into contact with the inflamed tissue being detected. For example, there is a barrier between the fluid and the source of the biomarker. In other words, the fluid obtained may have once directly come into contact with the inflamed tissue, but at the time that it is being extracted in accordance with the present invention, it is being separated from the inflamed tissue by a barrier.

[0015] As used herein, the term “peripheral” refers to anything outside of brain tissue. For example, a peripheral phagocyte may be obtained from cerebrospinal fluid (CSF). Phagocytes may include monocytes, macrophages, and/or lymphocytes. Such circulating phagocytes may be found in tissues, cells, and/or fluids in the body, for example in blood, peripheral blood mononuclear cells (PBMCs), synovial fluid, cerebrospinal fluid (CSF), central nervous system tissues, synovial fluid, cystic fluid, lymph fluid, ascites, pleural effusion, interstitial fluid, ocular fluids, vitreal fluid, urine the like, or a combination thereof. In some embodiments, the biomarker is an intracellular component. For example, the biomarker may be obtained from within a macrophage. In some embodiments, the macrophage sample is permeabilized. In some embodiments, the macrophage is lysed via various means, e.g., hypertonic solution treatment, detergent solution treatment, mechanical stress, etc.

[0016] Also, as used herein, “a fluid that does not directly come into contact with the inflamed tissue” is a fluid that is separated from the inflamed tissue by at least one barrier, e.g., a tissue membrane, a layer of cells, etc.

[0017] In some embodiments, one or more biomarkers are detected in the collected fluid sample. For example, a pattern of biomarkers may be detected in the sample. Detecting the biomarker or biomarkers indicates the presence of the inflammatory condition or a risk of the inflammatory condition. In some embodiments, detecting an increased level of the biomarker or biomarkers as compared to the level of the biomarker or biomarkers of a control sample indicates the presence of the inflammatory condition or a risk thereof. Control sample

is discussed below. In some embodiments, detecting a decreased level of the biomarker or biomarkers as compared to the level of the biomarker or biomarkers of a control sample indicates the presence of the inflammatory condition or a risk thereof.

[0018] In some embodiments, the inflammation condition that may be monitored or detected includes Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren’s Syndrome, and the like.

[0019] In some embodiments, the biomarker(s) is a neural-derived biomarker. However, the biomarker(s) is not limited to neural-derived biomarkers. In some embodiments, one or more biomarkers are detected in the sample, wherein the biomarkers are neural-derived, non-neural-derived biomarkers, or a combination thereof.

[0020] The biomarker(s) may be detected using a variety of methods. In some embodiments, the step of detecting the biomarker(s) in the sample may comprise introducing an antibody to the sample, wherein the antibody binds to the biomarker or is specific for the biomarker.

[0021] In some embodiments, this method of detecting an inflammatory condition is used in combination with one or more different methods for detecting the inflammatory disease. In some embodiments, this method is used to differentiate between one or more inflammatory conditions.

Neurological Conditions

[0022] The present invention also features a method of detecting a neurological condition. The method comprises (1) obtaining from a patient a fluid from outside of the patient’s brain tissue, wherein the fluid contains a circulating phagocyte, and (2) detecting a neurological condition-associated protein in the phagocyte. In some embodiments, one or more neurological condition-associated proteins are detected in the sample. The neurological condition-associated protein is associated with the neurological condition. Detecting the neurological condition-associated protein indicates the presence of the neurological condition or a risk of the neurological condition.

[0023] In some embodiments, detecting an increased level of the neurological condition-associated protein as compared to the level of the neurological condition-associated protein of a control sample indicates the presence of the neurological condition or a risk thereof. In some embodiments, detecting a decreased level of the neurological condition-associated protein as compared to the level of the neurological condition-associated protein of a control sample indicates the presence of the neurological condition or a risk thereof. Control sample is discussed below.

[0024] In some embodiments, the neurological condition that may be monitored or detected includes Alzheimer’s Disease, Parkinson’s Disease, Neuromyelitis Optica, transverse myelitis, Acute and chronic Stroke, and the like.

[0025] In some embodiments, the neurological condition-associated protein is derived from a brain source. In some embodiments, the neurological condition-associated protein is derived from a non-brain source. In some embodiments, one or more neurological condition-associated proteins is derived from a brain source, a non-brain source, or a combination thereof.

[0026] The neurological condition-associated protein may be present in a circulating phagocyte. Phagocytes may include monocytes, macrophages, and/or lymphocytes. Such circulating phagocytes may be found in tissues, cells, and/or

fluids in the body, for example in blood, peripheral blood mononuclear cells (PBMCs), cerebrospinal fluid (CSF), central nervous system tissues, synovial fluid, cystic fluid, lymph fluid, ascites, pleural effusion, interstitial fluid, ocular fluids, vitreal fluid, urine, the like, or a combination thereof. In some embodiments, the neurological condition-associated protein is an intracellular component. For example, the neurological condition-associated protein may be obtained from within a macrophage. In some embodiments, the macrophage sample is permeabilized. In some embodiments, the macrophage is lysed via various means, e.g., hypertonic solution treatment, detergent solution treatment, mechanical stress, etc.

[0027] In some embodiments, the step of detecting the neurological condition-associated protein in the sample may comprise introducing an antibody to the sample, wherein the antibody binds to the protein or is specific for the protein.

[0028] In some embodiments, this method is used in combination with one or more different methods for detecting the neurological condition. In some embodiments, this method is used to differentiate between one or more neurological conditions.

Multiple Sclerosis

[0029] The present invention also features methods of detecting multiple sclerosis or a risk of multiple sclerosis. In some embodiments, the method of the present invention may allow for monitoring, detecting and/or predicting a relapse or a remission of multiple sclerosis. In some embodiments, the method of detecting multiple sclerosis is used in combination with one or more methods of detecting multiple sclerosis. For example, the present methods may be used in conjunction with other modalities to monitor, detect or predicting a relapse or a remission of multiple sclerosis.

[0030] The method of detecting multiple sclerosis comprises (1) obtaining from a patient a fluid from outside of the patient's brain tissue, wherein the fluid contains a circulating phagocyte, and (2) detecting a multiple sclerosis-associated biomarker in the phagocyte. In some embodiments, one or more multiple sclerosis-associated proteins is detected in the phagocyte sample. The multiple sclerosis-associated biomarker is associated with multiple sclerosis. Detecting the multiple sclerosis-associated biomarker indicates the presence of multiple sclerosis or a risk of multiple sclerosis.

[0031] In some embodiments, detecting an increased level of the multiple sclerosis-associated biomarker as compared to the level of the multiple sclerosis-associated biomarker of a control sample indicates the presence of multiple sclerosis or a risk thereof. In some embodiments, detecting a decreased level of the multiple sclerosis-associated biomarker as compared to the level of the multiple sclerosis-associated biomarker of a control sample indicates the presence of multiple sclerosis or a risk thereof. In some embodiments, detecting an increased level of one class of multiple sclerosis-associated biomarker and a decreased of another class of multiple sclerosis-associated biomarker as compared to the respective level of the multiple sclerosis-associated biomarker of a control sample indicates the presence of multiple sclerosis or a risk thereof.

[0032] In some embodiments, the sample is obtained from the mammal immediately following a relapse (e.g., exacerbation of symptoms) before a drug (e.g., a steroid) treatment has begun. In some embodiments, the sample is obtained

from the mammal before a relapse. In some embodiments, the sample is obtained during the course of the drug (e.g., steroid) treatment.

[0033] The multiple sclerosis-associated biomarker may be present in a circulating phagocyte. Phagocytes may include monocytes, macrophages, and/or lymphocytes. For example, macrophages are a type of monocyte and are phagocytic cells important in both specific cell-mediated immunity and non-specific innate immunity. Circulating phagocytes may be found in tissues, cells, and/or fluids in the body, for example in blood, peripheral blood mononuclear cells (PBMCs), cerebrospinal fluid (CSF), central nervous system tissues, synovial fluid, cystic fluid, lymph fluid, ascites, pleural effusion, interstitial fluid, ocular fluids, vitreal fluid, urine, the like, or a combination thereof. In some embodiments, the neurological condition-associated protein is an intracellular component. For example, the neurological condition-associated protein may be obtained from within a macrophage. In some embodiments, the macrophage sample is permeabilized.

[0034] As used herein, a mammal includes a human, a mouse, a rat, a llama, a rabbit, a dog, a primate, a guinea pig, a cat, a hamster, a pig, a chicken, a goat, a horse, or a cow.

[0035] In some embodiments, the multiple sclerosis-associated biomarker is a Tau protein (or a fragment thereof) or a Tau protein (or fragment thereof) comprising a phosphorylated residue (e.g., a phosphorylated serine residue, a phosphorylated threonine residue). In some embodiments, the phosphorylated residue is serine 214, serine 235, serine 262, serine 356, serine 396, serine 404, serine 413, serine 46, serine 515, serine 516, serine 519, serine 531, serine 552, serine 610, serine 622, serine 641, serine 713, serine 721, serine 726, serine 730, serine 739, threonine 181, threonine 205, threonine 470, threonine 492, threonine 498, threonine 522, threonine 529, threonine 534, threonine 548, the like, or a combination thereof.

[0036] In some embodiments, phosphorylation of Tau can decrease its solubility. In some embodiments, the method of detecting multiple sclerosis comprises detecting a level of insoluble Tau protein in the sample. In some embodiments, an increased level of insoluble Tau protein as compared to a control level of insoluble Tau protein is indicative of multiple sclerosis or a risk thereof.

[0037] In some embodiments, the multiple sclerosis-associated biomarker is a protein or a fragment thereof selected from the group consisting of neuroglobin, valosin-containing protein, brain hexokinase, hippocalcin-1, nestin, synaptotagmin, myelin associated glycoprotein, transketolase, NS1 associated protein 1, major vault protein, synaptojanin, enolase, alpha synuclein, glial fibrillary acidic protein, S-100 proteinNeu-N, 26S proteasome subunit 9, annexin A2, annexin A3, annexin A5, annexin A6, annexin A11, ubiquitin activating enzyme ZE1, ubiquitin B precursor, vimentin, glyceraldehyde-3-phosphate dehydrogenase, 13-3-3 protein.

[0038] The multiple sclerosis-associated biomarker (e.g., Tau protein or fragment thereof) may be of various lengths. For example, in some embodiments, the multiple sclerosis-associated biomarker consists of between about 5 to 20 amino acids. In some embodiments, the multiple sclerosis-associated biomarker consists of about 20 to 40 amino acids. In some embodiments, the multiple sclerosis-associated biomarker consists of about 40 to 80 amino acids. In some embodiments, the multiple sclerosis-associated biomarker consists of about 80 to 150 amino acids. In some embodiments, the multiple sclerosis-associated biomarker consists of about 150

to 200 amino acids. In some embodiments, the multiple sclerosis-associated biomarker consists of about 200 to 300 amino acids. In some embodiments, the multiple sclerosis-associated biomarker consists of about 300 to 400 amino acids. In some embodiments, the multiple sclerosis-associated biomarker consists of about 400 to 500 amino acids. In some embodiments, the multiple sclerosis-associated biomarker consists of about 500 to 600 amino acids.

[0039] The multiple sclerosis-associated biomarker (e.g., Tau protein or fragment thereof) may comprise various regions of the full-length protein. For example, in some embodiments, the multiple sclerosis-associated biomarker comprises the amino-terminus (e.g., N-terminus, NH₂-terminus, N-terminal end, amine-terminus). The amino-terminus refers to the amino acid at the end of a protein or polypeptide that has a free amine group (—NH₂). In some embodiments, the multiple-sclerosis associated biomarker consists of about the first 15 amino acids. In some embodiments, the multiple-

sclerosis associated biomarker consists of about the first 25 amino acids. In some embodiments, the multiple-sclerosis associated biomarker consists of about the first 50 amino acids. In some embodiments, the multiple-sclerosis associated biomarker consists of about the first 75 amino acids. In some embodiments, the multiple-sclerosis associated biomarker consists of about the first 100 amino acids. In some embodiments, the multiple-sclerosis associated biomarker consists of about the first 125 amino acids.

[0040] In some embodiments, the multiple-sclerosis associated biomarker or fragment thereof comprises the carboxy-terminus (e.g., C-terminus, COOH-terminus, C-terminal end, carboxyl-terminus). The carboxy-terminus refers to the amino acid at the end of a protein or polypeptide that has a free carboxylic acid group (—COOH). In some embodiments, the multiple-sclerosis associated biomarker consists of about the last 100 amino acids.

[0041] Table 1 shows the amino acid sequence of full-length human Tau protein.

1) TABLE 1

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
758 AA [This is the length of the unprocessed precursor]	78,878 Da [This is the MW of the unprocessed precursor]	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPPELLK QLLGDLHQEG PPLKGAGGKE RPGSKKEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDPGPSVG RAKGQDAPLE FTFHVETPN VQKEQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKPAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKINRCL SPKLP TPGSS DPLIQSSPA VCEPPSSPK HVSSVTSRTG SSGAKEMKLG GADGKTKIAT PRGAAPPGQK GQANATRI PA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDDL KNVSKIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV DLSKVTSKCG SLGNIHHPKG GGQVEVKSEK LDFKDRVQSK IGSLDNITHV PGGGNKKIET HKLTFRENAK AKTDHGAEIV YKSPVVS GDT SPRHLSNVSS TGSIDMVDSP QLATLADEV S ASLAKQGL	1-758	1

[0042] Table 2 shows examples of some of the possible multiple sclerosis-associated biomarkers (e.g., Tau protein or a fragment thereof).

1) TABLE 2

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
10	1235.4	MAEPRQEFEV	1-10	2
20	2310.58	MAEPRQEFEV MEDHAGTYGL	1-20	3
30	3388.69	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT	1-30	4

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
40	4545.84	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD	1-40	5
50	5571.02	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT	1-50	6
60	6570	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG	1-60	7
70	7574.04	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP	1-70	8
80	8571.17	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV	1-80	9
90	9496.14	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA	1-90	10
100	10556.29	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG	1-100	11
110	11501.26	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD	1-110	12
120	12472.27	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG	1-120	13
130	13565.44	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK	1-130	14
140	14720.77	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP	1-140	15
150	15738.98	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM	1-150	16
160	16660.12	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP	1-160	17
170	17782.35	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP	1-170	18
180	18713.25	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG	1-180	19

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
		HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG		
190	19822.58		1-190	20
200	20879.8	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMRGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG	1-200	21
210	21847.88	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE	1-210	22
220	23050.05	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE	1-220	23
230	24062.07	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ	1-230	24
240	25070.18	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ DSPPSKASPA	1-240	25
250	26125.36	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA	1-250	26
260	27062.44	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP	1-260	27
270	28148.74	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG	1-270	28

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
		HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD		
280	29145.79	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP	1-280	29
290	30141.88	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDPGSVG	1-290	30
300	31313.22	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKFSPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP FGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDPGSVG RAKQDAPLE	1-300	31
310	32422.47	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDPGSVG RAKQDAPLE FTFHVEITPN	1-310	32
320	33510.63	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDPGSVG RAKQDAPLE FTFHVEITPN VQKQAHSEE	1-320	33
330	34449.64	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD	1-330	34

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
		FLSKVSTEIP ASEPDPGSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA		
340	35433.69	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDPGSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEAPEARGP	1-340	35
350	36529.87	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDPGSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEAPEARGP SLGEDTKEAD	1-350	36
360	37535.06	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDPGSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEAPEARGP SLGEDTKEAD LPEPSEKQPA	1-360	37
370	38611.37	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDPGSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEAPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR	1-370	38
380	39701.64	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDPGSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEAPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS	1-380	39
390	40719.73	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG	1-390	40

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
		SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTTEIPEG TTAEAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEAPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD		
400	41806.98	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTTEIPEG TTAEAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEAPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS	1-400	41
410	42900.36	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTTEIPEG TTAEAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEAPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL	1-410	42
420	43892.47	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTTEIPEG TTAEAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEAPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLPTPGSS	1-420	43
430	44857.59	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTTEIPEG TTAEAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEAPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLPTPGSS DPLIQSSPA	1-430	44

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
440	45867.71	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEP TTAEEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKNRPCL SPKLPTPGSS DPLIQSSPA VCPEPPSSPK	1-440	45
450	46828.72	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEP TTAEEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG PAKQDAPLE FTFHVFTPN VQKEQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKNRPCL SPKLPTPGSS DPLIQSSPA VCPEPPSSPK HVSSVTSRTG	1-450	46
460	47858.97	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEP TTAEEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKNRPCL SPKLPTPGSS DPLIQSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLLK	1-460	47
470	48822.13	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEP TTAEEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDSSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKNRPCL SPKLPTPGSS DPLIQSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLLK GADGKTKIAT	1-470	48
480	49775.15	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEP TTAEEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM	1-480	49

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
		SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEQPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKLRPCL SPKLPTPGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLK GADGKTKIAT PRGAAPPQK		
490	50804.42	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGDSSEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEQPEARGP SLGEDTKEAD LPEPSSKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKLRPCL SPKLPTPGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLK GADGKTKIAT PRGAAPPQK GQANATRIPA	1-490	50
500	51782.51	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGDSSEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP APGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEQPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKLRPCL SPKLPTPGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP	1-500	51
410	52807.56	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGDSSEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEQPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKLRPCL SPKLPTPGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPKSGD	1-510	52
520	53701.53	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGDSSEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG	1-520	53

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
		GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGSPVG RAKGQDAPLE FTFHVEITPN VQKQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLPTPGSS DPLIQSSSPA VCPEPPSSPK HVSVTSRTG SSGAKEMKLGADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP		
530	54735.74	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGSPVG RAKGQDAPLE FTFHVEITPN VQKQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLPTPGSS DPLIQSSSPA VCPEPPSSPK HVSVTSRTG SSGAKEMKLGADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP	1-530	54
540	55677.7	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKDA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGSPVG RAKGQDAPLE FTFHVEITPN VQKQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLPTPGSS DPLIQSSSPA VCPEPPSSPK HVSVTSRTG SSGAKEMKLGADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP	1-540	55
550	56295.63	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP ASGAIPLPVD FLSKVSTEIP ASEPDGSPVG RAKGQDAPLE FTFHVEITPN VQKQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLPTPGSS DPLIQSSSPA VCPEPPSSPK HVSVTSRTG SSGAKEMKLGADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP	1-550	56

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
560	57337.84	MAEPRQEPEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKESPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKNRPCL SPKLPTPGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLGK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPPTREP KKVAVVRTPP KSPSSAKSRL	1-560	57
570	58388.1	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDEGSEEPG SETSDAKSTP TAEDVTAPLV DPGAPGKQAA AQPHEIPEG TTAEAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKNRPCL SPKLPTPGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLGK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPMDL	1-570	58
580	59431.32	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAEAGIGD TPSLEDEAAG AVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLP FTFHVEITPN VQKEQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKNRPCL SPKLPTPGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLGK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPMDL KNVSKIGST	1-580	59
590	60449.41	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPQA	1-590	60

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
		PGEQPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKLRPCL SPKLPTPGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLLK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSYSSPGSP GTPGSRSRTP SLPTPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDL KNVKSIGST ENLKHQGGG		
600	61629.85	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDETEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGSPV RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAPPGA PGEQPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKLRPCL SPKLPTPGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLLK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSYSSPGSP GTPGSRSRTP SLPTPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDL KNVKSIGST ENLKHQGGG KVQIINKKLD	1-600	61
610	62633.98	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDETEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGSPV RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAPPGA PGEQPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKLRPCL SPKLPTPGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLLK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSYSSPGSP GTPGSRSRTP SLPTPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDL KNVKSIGST ENLKHQGGG KVQIINKKLD LSNVQSKCGS	1-610	62
620	63680.16	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDETEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGSPV RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAPPGA PGEQPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKLRPCL SPKLPTPGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLLK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSYSSPGSP GTPGSRSRTP SLPTPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDL	1-620	63

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
		KNVKSIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPGG		
630	64751.44	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDETEG GRHAPPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKKEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAPPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKLRPCL SPKLPTPGSS DPLIQSSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLG GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDL KNVKSIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV	1-630	64
640	65770.63	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDETEG GRHAPPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKKEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAPPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKLRPCL SPKLPTPGSS DPLIQSSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLG GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDL KNVKSIGST FNLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV DLSKVTSCCG	1-640	65
650	66811.8	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDETEG GRHAPPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKKEVDE DRDVESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAPPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKLRPCL SPKLPTPGSS DPLIQSSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLG GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDL KNVKSIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV DLSKVTSCCG SLGNIHHPG	1-650	66

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
660	67853.95	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSD KKAKTSTRSS AKTLKLRPCL SPKLPTGSS DPLIQSSPA VCEPPSSPK HVSSVTSRTG SSGAKEMKLGADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRRTPLPTPTREP KKVAVVTRTP KSPSSAKSRL QTAPVMPDL KNVSKIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPVG GSVQIVYKPV DLSKVTSCG SLGNIHHPG GQVEVKSEK	1-660	67
670	69071.34	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSD KKAKTSTRSS AKTLKLRPCL SPKLPTGSS DPLIQSSPA VCEPPSSPK HVSSVTSRTG SSGAKEMKLGADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRRTPLPTPTREP KKVAVVTRTP KSPSSAKSRL QTAPVMPDL KNVSKIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPVG GSVQIVYKPV DLSKVTSCG SLGNIHHPG GQVEVKSEK LDFKDRVQSK	1-670	68
680	70121.52	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSD KKAKTSTRSS AKTLKLRPCL SPKLPTGSS DPLIQSSPA VCEPPSSPK HVSSVTSRTG SSGAKEMKLGADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRRTPLPTPTREP KKVAVVTRTP KSPSSAKSRL QTAPVMPDL KNVSKIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPVG GSVQIVYKPV DLSKVTSCG SLGNIHHPG GQVEVKSEK LDFKDRVQSK IGLDNI THV	1-680	69

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
690	71103.62	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAPPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLTPGSS DPLIQPSSPA VCEPPSSPK HVSSVTSRTG SSGAKEMKLLK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRRTPT SLPTPPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDDL KNVSKIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVP GG SVQIVYKPV DLSKVTSKCG SLGNIHHPG GGQVEVKSEK LDFKDRVQSK IGSLDNITHV PGGGNKKIET	1-690	70
70072329.04		MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAPPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLTPGSS DPLIQPSSPA VCEPPSSPK HVSSVTSRTG SSGAKEMKLLK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRRTPT SLPTPPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDDL KNVSKIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVP GG SVQIVYKPV DLSKVTSKCG SLGNIHHPG GGQVEVKSEK LDFKDRVQSK IGSLDNITHV PGGGNKKIET HKLTFRENAK	1-700	71
710	73351.17	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAPPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLTPGSS DPLIQPSSPA VCEPPSSPK HVSSVTSRTG SSGAKEMKLLK GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRRTPT SLPTPPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDDL KNVSKIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVP GG SVQIVYKPV DLSKVTSKCG SLGNIHHPG GGQVEVKSEK LDFKDRVQSK IGSLDNITHV PGGGNKKIET	1-710	72

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
		HKLTFRENAK AKTDHGAEIV		
720	74385.31	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKKEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLPPTGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLG GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDL KNVSKIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV DLSKVTSKCG SLGNIHHKPG GGQVEVKSEK LDFKDRVQSK IGSLDNI THV PGGGNKKIET HKLTFRENAK AKTDHGAEIV YKSPVVS GDT	1-720	73
730	75450.47	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKKEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLPPTGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLG GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDL KNVSKIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV DLSKVTSKCG SLGNIHHKPG GGQVEVKSEK LDFKDRVQSK IGSLDNI THV PGGGNKKIET HKLTFRENAK AKTDHGAEIV YKSPVVS GDT SPRHLSNVSS	1-730	74
740	76804.91	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHEIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKKEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKRNRPCL SPKLPPTGSS DPLIQPSSPA VCPEPPSSPK HVSSVTSRTG SSGAKEMKLG GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDL	1-740	75

1) TABLE 2-continued

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
		KNVSKIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV DLSKVTSKCG SLGNIHHKPG GGQVEVKSEK LDFKDRVQSK IGSLDNITHV PGGGNKKIET HKLTFRENAK AKTDHGAEIV YKSPVVS GDT SPRHLSNVSS TGSIDMVDSP		
750	78109.39	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGQAA AQPHTIPEG TTAEAGIGD TPSLEDEAAG HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP SGPREATRQP SGTGPEDETEG GRHAPPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGFSVG RAKGQDAPLE FTFHVETPN VQKEQAHSEE HLGRAAFPQA PGEPEARGP SLGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARMVS KSKDGTGSD KKAKTSTRSS AKTLKRNPC LSPKLTPGSS DPLIQSSPA VCPEPPSPK HVSSVTSRTG SSGAKEMKLG GADGKTKIAT PRGAAPPQK GQANATRIPA KTPPAKTPP SSGEPPKSGD RSYSSPGSP GTPGSRSRTP SLPTPPTREP KKVAVVRTPP KSPSSAKSRL QTAPVMPDL KNVSKIGST ENLKHQPGGG KVQIINKKLD LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV DLSKVTSKCG SLGNIHHKPG GGQVEVKSEK LDFKDRVQSK IGSLDNITHV PGGGNKKIET HKLTFRENAK AKTDHGAEIV YKSPVVS GDT SPRHLSNVSS TGSIDMVDSP QLATLADEV S	1-750	76
10	1815.06	QLATLADEV S ASLAKQGL	749-758	77
20	2818.17	TGSIDMVDSP QLATLADEV S ASLAKQGL	739-758	78
30	2992.33	SS TGSIDMVDSP QLATLADEV S ASLAKQGL	729-758	79
40	4099.53	DT SPRHLSNVSS TGSIDMVDSP QLATLADEV S ASLAKQGL	719-758	80

[0043] In some embodiments, the step of detecting the multiple sclerosis-associated biomarker in the sample may comprise introducing an antibody to the sample, wherein the antibody binds to the multiple sclerosis-associated biomarker.

[0044] In some embodiments, the step of detecting the multiple sclerosis-associated biomarker in the sample comprises subjecting the sample to a western blot, an enzyme-linked immunosorbent assay (ELISA), a lateral flow assay, a radioimmunoassay, an immunohistochemistry assay, a bioluminescent assay, a chemiluminescent assay, a mass spectrometry assay, a flow cytometry assay (e.g., fluorescence-activated cell sorting (FACS)), or a combination thereof and the like. Such assays are well known in the art.

[0045] In some embodiments, the step of detecting the multiple sclerosis-associated biomarker further comprises contacting the sample with an antibody that binds to the multiple sclerosis-associated biomarker and detecting an antibody-biomarker complex. The step of detecting an antibody-biomarker complex may comprise subjecting the sample to a micro array, western blot, an enzyme-linked immunosorbent assay (ELISA), a lateral flow assay, a radioimmunoassay, an immunohistochemistry assay, a bioluminescent assay, a chemiluminescent assay, a flow cytometry assay (e.g., fluorescence-activated cell sorting (FACS)), or a combination thereof and the like.

minescent assay, a flow cytometry assay (e.g., fluorescence-activated cell sorting (FACS)), or a combination thereof and the like. In some embodiments, detecting the antibody-biomarker complex indicates the presence of multiple sclerosis or a risk of multiple sclerosis.

[0046] As described above, in some embodiments, the step of detecting the multiple sclerosis-associated biomarker may comprise subjecting the sample fluorescence-activated cell sorting (FACS). Fluorescence-activated cell sorting (FACS) is a type of flow cytometry that sorts a mixture of biological cells, one at a time, into separate containers based upon the specific light scattering and fluorescent characteristics of each cell. It provides quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest. Generally, a current of a rapidly flowing stream of liquid carries a suspension of cells through a nozzle. The flow is selected such that there is a large separation between cells relative to their diameter. Vibrations at the tip of the nozzle cause the stream of cells to break into individual droplets, and the system is adjusted so that there is a low probability of more than one cell being in a droplet. A monochromatic laser beam illuminates the droplets, which are electronically monitored by fluorescent detectors. The

droplets that emit the proper fluorescent wavelengths are electrically charged between deflection plates in order to be sorted into collection tubes.

[0047] As described above, in some embodiments, the step of detecting the multiple sclerosis-associated biomarker may comprise subjecting the sample to an enzyme-linked immunosorbent assay (ELISA). ELISA is an assay used to detect the presence of an antibody or a biomarker in a sample. Generally, in ELISA, a sample containing an unknown amount of biomarker, e.g., an antigen, is affixed/immobilized to a surface (e.g., a polystyrene microtiter plate). Then, an antibody that binds to the antigen of interest is washed over the surface so that it can bind the antigen and form an antibody/antigen complex. In some cases, this antibody is covalently linked to an enzyme. In some cases, the antibody is not covalently linked to an enzyme but can be detected by a secondary antibody that is linked to an enzyme. In the final step, a substance (e.g., substrate) that the enzyme is capable of converting to a detectable visible signal (e.g., color signal) is added to the reaction. Thus, if the antibody/antigen complex is present, the substrate will be converted to the detectable visible signal, and then amount of antigen in the sample can be measured.

[0048] As mentioned above, in some embodiments, an antibody is used to detect the presence of the multiple sclerosis-associated biomarker. The multiple sclerosis-associated biomarker may be detected with a variety of antibodies. In some embodiments, the antibody is a monoclonal or a polyclonal antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a chimera. In some embodiments, the antibody is derived from a human, a mouse, a rat, a llama, a rabbit, a dog, a primate, a guinea pig, a cat, a hamster, a pig, a chicken, a goat, a horse, or a cow. In some embodiments, the antibody is synthetic. In some embodiments, the antibody is a recombinant antibody.

[0049] Frequently, antibodies are labelled either covalently or non-covalently by combining the antibody with a second substance that provides for detectable signal. A wide variety of labels and conjugation techniques are known in the art and are reported extensively in both the scientific and patent literature. Examples of labels include but are not limited to radioisotopes, enzymes, substrates, cofactors, inhibitors, fluorescers, chemiluminescers, magnetic particles, and the like. In some embodiments of the present invention, the antibody comprises a label.

[0050] In some embodiments, the present invention is used to detect the presence of multiple sclerosis. For example, a patient may present with symptoms of a demyelinating disease, and he or she is tested for an elevated level of a multiple sclerosis-associated biomarker. If, according to the present invention, the level of a multiple sclerosis-associated biomarker is elevated and the patient presents symptoms of a demyelinating disease, then the patient is diagnosed as having multiple sclerosis.

[0051] In some embodiments, the present invention is used to detect a risk of multiple sclerosis. For example, a patient may present with no symptoms of a demyelinating disease, but he or she wishes to be tested for a risk of multiple sclerosis. If, according to the present invention, the level of a multiple sclerosis-associated biomarker is elevated and the patient does not present symptoms of a demyelinating disease, then the patient is diagnosed as having a risk of multiple sclerosis.

[0052] As used herein, the term "elevated level" refers to a level that is higher than the normal level of the multiple sclerosis-associated biomarker (e.g., the level that would be detected in a person who does not have multiple sclerosis). To identify the level of the multiple sclerosis-associated biomarker that is the normal level, samples are pooled from about, for example, 500 patients (or an appropriate number of patients that would be statistically meaningful) who do not experience any symptoms of multiple sclerosis (or other demyelinating diseases) and who do not test positive for multiple sclerosis as detected by MRI. From those pooled samples, the average level of the multiple sclerosis-associated biomarker can be quantified and then defined as being the normal level of the multiple sclerosis-associated biomarker. If the normal level of the multiple sclerosis-associated biomarker is about zero, then an elevated level refers to any level that is greater than zero, for example, about 5 units, about 25 units, about 50 units, about 100 units, about 500 units, about 1000 units, about 10,000 units, about 100,000 units, about 1,000,000 units. In some embodiments, a unit may be an absorbance unit (e.g., from an ELISA), a percent positive (e.g., from a flow cytometry or FACS assay), or a fluorescence unit.

[0053] If the normal level of the multiple sclerosis-associated biomarker is some positive value (e.g., 5 units, 10 units, 50 units, 100 units, 500 units), then an elevated level refers to any level that is higher than the normal level. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 10-20% higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 20-30% higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 30-40% higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 40-50% higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 50-60% higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 60-70% higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 70-80% higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 80-90% higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 90-100% higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 1-2 fold higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 2-3 fold higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated

level of the multiple sclerosis-associated biomarker may be a level that is about 3-4 fold higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 4-5 fold higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 5-10 fold higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 10-20 fold higher than the normal level of the multiple sclerosis-associated biomarker. In some embodiments, an elevated level of the multiple sclerosis-associated biomarker may be a level that is about 20-50 fold higher than the normal level of the multiple sclerosis-associated biomarker.

[0054] The present invention also provides a method of monitoring the progression of multiple sclerosis and/or monitoring the treatment of multiple sclerosis. For example, in some embodiments, the present invention may be used to measure the level of the multiple sclerosis-associated biomarker in order to detect a change in the level (e.g., an increase in the level, a decrease in the level, a maintaining of the level). Without wishing to limit the present invention to any theory or mechanism, a change in the level of the multiple sclerosis-associated biomarker may correlate with a change in the patient's status (e.g., remission, progression, worsening). For example, a decrease in the level of the multiple sclerosis-associated biomarker may indicate the patient has entered or will enter a remission period. In some embodiments, the present invention may be used to monitor the level of the multiple sclerosis-associated biomarker in a patient while the patient is on a treatment regimen (e.g., a drug). Without wishing to limit the present invention to any theory or mechanism, a treatment regimen (e.g., a drug) that is effective at inhibiting the progression of multiple sclerosis and/or reducing the symptoms of multiple sclerosis may decrease the level of the multiple sclerosis-associated biomarker in the patient.

[0055] As mentioned above, in some embodiments, the method of the present invention for detecting multiple sclerosis is used in combination with one or more different methods for detecting multiple sclerosis. For example, in some cases, a combination of family history, a physical exam, and magnetic resonance imaging (MRI) findings are used to diagnose multiple sclerosis. Currently, MRI is the most sensitive radiographic technique for the imaging of multiple sclerosis. Multiple sclerosis plaques are commonly seen as round or void discrete lesions in the periventricular white matter. Other common locations for multiple sclerosis plaques include the corpus callosum, corona radiata, internal capsule, and centrum semiovale. In some embodiments, the present invention is used to measure a multiple sclerosis-associated biomarker, and the level of the multiple sclerosis-associated biomarker is correlated with a magnetic resonance imaging (MRI) measurement. Without wishing to limit the present invention to any theory or mechanism, it is believed that elevated levels of the multiple sclerosis-associated biomarker correlate with a MRI scan showing the presence of multiple sclerosis plaques in the brain.

[0056] The method of the present invention for detecting multiple sclerosis may be used in combination with one or more methods for detecting a different condition. For example, the method of the present invention may also help to

distinguish multiple sclerosis from other diseases with similar clinical manifestations. For example, neuromyelitis optica (NMO), also known as Devic's syndrome, is a neurological disorder regarded as a severe variant of multiple sclerosis. The characteristic inflammatory demyelinating lesions of NMO selectively and repeatedly affect the optic nerves and the spinal cord, causing blindness and paralysis. A marker (e.g., aquaporin-4 antibodies) has been identified in serum and cerebrospinal fluid of patients with NMO, and the presence of a NMO marker (e.g., aquaporin-4 antibodies) may be used to distinguish NMO from multiple sclerosis. In some embodiments, the method of detecting the presence of multiple sclerosis or a risk of multiple sclerosis comprises detecting the presence or absence of at least two biomarkers (e.g., proteins, antigens, or the like) wherein at least one biomarker is detected in order to distinguish multiple sclerosis from a disease with similar clinical manifestations.

[0057] In some embodiments, the method of detecting the presence of multiple sclerosis or a risk of multiple sclerosis comprises detecting an elevated level of two or more multiple sclerosis-associated biomarkers. In some embodiments, the method of detecting the presence of multiple sclerosis or a risk of multiple sclerosis comprises detecting an elevated level of three or more multiple sclerosis-associated biomarkers.

[0058] The present invention also provides a method of diagnosing multiple sclerosis at an early stage of the disease before all clinical criteria are fulfilled thus justifying early initiation of a multiple sclerosis-appropriate therapy.

A Kit for Detecting the Presence of Multiple Sclerosis

[0059] The present invention also features a kit for detecting the presence of multiple sclerosis or a risk of multiple sclerosis in a circulating phagocyte sample derived from a mammal. The kit comprises an antibody that binds to a multiple sclerosis-associated biomarker. In some embodiments, the kit further comprises a means for detecting the binding of the antibody to the multiple sclerosis-associated biomarker/antigen in the sample (e.g., an antibody-antigen complex). In some embodiments, the detecting of an elevated level of an antibody-antigen complex indicates presence of multiple sclerosis or a risk of multiple sclerosis.

[0060] In some embodiments, the kit comprises an antibody, wherein the antibody is a monoclonal or a polyclonal antibody. In some embodiments, the antibody is derived from a human, a mouse, a rat, a llama, a rabbit, a dog, a primate, a guinea pig, a cat, a hamster, a pig, a chicken, a goat, a horse, or a cow. In some embodiments, the antibody is humanized. In some embodiments, the antibody is a chimera. In some embodiments, the antibody is specific for the multiple sclerosis-associated biomarker.

Example 1

Detecting Multiple Sclerosis in a Patient

[0061] The following example describes the detection of multiple sclerosis in a patient according to two methods disclosed in the present invention. A 24-year-old male patient presents to his primary care physician complaining of changes in vision, limb weakness, and extreme fatigue. He mentions his symptoms have been recurring over the last 3 months. The physician suspects the possibility of a tumor in the central nervous system (CNS) or a CNS disease, as well as multiple sclerosis. The physician obtains a blood sample to be

sent to a diagnostic laboratory for multiple sclerosis testing, and also refers the patient to a neurologist.

[0062] The laboratory receives the patient's blood sample collected in a CPT tube. PBMCs are obtained from a BD Vacutainer™ CPT tube using a cell separation procedure. The cells are washed three times in 1X PBS and centrifuged in a horizontal rotor (swing-out head) for a minimum of 5 minutes at 1200 to 1500 RCF (Relative Centrifugal force). The supernatant is removed and the cells are resuspended in 1X PBS. After the final wash, extracts of the PBMCs are prepared by lysing with a hypotonic solution or other method. Then the lysate is subjected to assay involving an antibody that binds to Tau protein fragment comprising the phosphorylated serine residue Ser-404. The assay indicates that an elevated level of said Tau protein fragment is present in the PBMCs. The assay is the assay of example 2 or example 3. Thus, the results of the assay indicate that the patient has multiple sclerosis. The physician notifies the patient, who then begins treatment immediately.

[0063] The laboratory receives the patient's blood sample collected in a CPT tube. PBMCs are obtained from a BD Vacutainer™ CPT tube using a cell separation procedure. The cells are washed three times in 1X PBS and centrifuged in a horizontal rotor (swing-out head) for a minimum of 5 minutes at 1200 to 1500 RCF (Relative Centrifugal force). The supernatant is removed and the cells are resuspended in 1X PBS. The cells are then subjected to assay involving an antibody that binds to Tau protein fragment comprising the phosphorylated serine residue Ser-404. The assay is the assay of example 4.

Example 2

Direct ELISA Assay Protocol

[0064] The following example describes a direct ELISA assay used for detecting a multiple sclerosis-associated antigen in a sample. The protein concentration of the sample is determined using the BioRad™ (Bradford method) assay. MicroELISA plates are coated by addition of 100 µL of a 5-20 µg/mL solution of the sample, which is then incubated for 1 hour at 21° C. The wells are washed out with phosphate buffered solution (PBS) with 0.05% polysorbate (Tween 20™). The wells are then filled with 0.1 M glycine in PBS and incubated for 1 hour at 21° C. to block unoccupied binding sites. After rewashing the wells, 100 µL of an appropriate dilution of antibody in PBS-0.05% Tween™ 20 with 1% bovine serum albumin (BSA) is added and incubated for 1 hour at 21° C. The unbound antibody is then washed out with three exchanges of PBS-0.05% Tween™ 20. One hundred µL of an appropriately diluted horse radish peroxidase conjugated anti-immunoglobulin G (IgG) in PBS-0.05% Tween™ 20-1% BSA is then added to each well and incubated for 1 hour at 21° C. The wells are then washed twice with PBS-0.05% Tween™ 20 and finally with PBS. One hundred µL of soluble MTB substrate solution is added to each well and incubated for 30 minutes at 21° C. after which 100 µL of MTB stop reagent is added and the color intensity is measured at 450 nm using an ELISA plate reader.

[0065] Appropriate dilutions of the antigen and antibody are established by performing checkerboard titrations. Antigen concentrations in samples are interpolated from standard curves.

Example 3

Indirect ELISA Assay Protocol

[0066] The following example describes an indirect ELISA assay used for detecting a multiple sclerosis-associated anti-

gen in various samples. This assay is constructed using polyclonal and monoclonal antibodies. ELISA wells are coated with polyclonal antibody at an appropriate concentration and the wells are washed and blocked as described above. Various dilutions of antigen containing samples are added to the wells and incubated for 1 hour at 21° C., after which the wells are washed 3 times with PBS-0.05% Tween™ 20. The monoclonal antibody is then added at an appropriate dilution in PBS-0.05% Tween™ 20-1% BSA and incubated for 1 hour at 21° C. The wells are then washed 3 times and an appropriately diluted horse radish peroxidase conjugated anti-mouse IgM in PBS-0.05% Tween™ 20-1% BSA is then added to each well and incubated for 1 hour at 21° C. The wells are then washed twice with PBS-0.05% Tween™ 20 and finally with PBS. One hundred µL of soluble MTB substrate solution is added to each well and incubated for 30 minutes at 21° C. after which 100 µL of MTB stop reagent is added and the color intensity is measured at 450 nm using an ELISA plate reader.

[0067] Appropriate dilutions of antigen and antibody are established by performing checkerboard titrations. Antigen concentrations in samples are interpolated from standard curves.

Example 4

Flow Cytometry Protocol

[0068] The following example describes a flow cytometry assay used for detecting a multiple sclerosis-associated antigen in various samples. PBMCs from multiple sclerosis (MS) subjects and control subjects are stained with fluorescent antibodies to the multiple sclerosis-associated antigen (e.g., Tau protein) and also with fluorescent labeled antibodies to cluster designation (CD) 3 T-lymphocyte marker or CD 19 B-Lymphocyte marker, CD68 intracellular monocyte marker and CD14 monocyte/macrophage cell surface marker. The labeled cells are analyzed by flow cytometry for qualitative or quantitative differences.

[0069] PBMCs are obtained from a BD Vacutainer™ CPT tube using a cell separation procedure. The cells are washed three times in 1X PBS and centrifuged in a horizontal rotor (swing-out head) for a minimum of 5 minutes at 1200 to 1500 RCF (Relative Centrifugal force). The supernatant is removed and the cells are resuspended in 1X PBS. After the final wash, the cells are resuspended to approximately 4.0 mL in 1X PBS. Approximately 50 µL of the cell suspension to be analyzed is transferred into tubes for double staining with selected antibody pairs. Ten µL of 40 mg/mL normal human IgG (Sigma-Aldrich) for a total of 400 µg is added to each tube to block FC binding. The appropriate cell surface monoclonal antibodies CD3 PE, CD19 PE or CD14 PE are added at this time and incubated for 20 minutes at room temperature.

[0070] One hundred µL of Dako Intrastain™ Reagent A (fixative) is added to each tube and then mixed gently with a vortex mixer to ensure that the cells are in suspension. Cells are incubated at room temperature for 15 minutes. Two mL of 1X PBS working solution is added to each test tube and mixed gently. The tubes are centrifuged at 300xg for 5 minutes. Supernatant is aspirated leaving about 50 µL of fluid. The fluid is mixed thoroughly to ensure that the cells are in suspension.

[0071] One hundred µL of Dako Intrastain™ Reagent B (permeabilization) is added to each tube. The appropriate amount of the antibody specific for the multiple sclerosis-associated antigen is added to the appropriate tubes. The

tubes are mixed gently to ensure that the cells are in suspension and incubated at room temperature for 15-60 minutes. Two mL of 1X PBS working solution is added to each test tube and mixed gently. The tubes are centrifuged at 300×g for 5 minutes, and then the supernatant is aspirated, leaving approximately 50 µl of fluid. The fluid is mixed thoroughly to ensure that the cells are in suspension.

[0072] One hundred µL of Dako Intrastain™ Reagent B (permeabilization) is added to each tube. The appropriate volume of the 2nd step antibody conjugated to FITC (specific to the multiple sclerosis-associated antigen) is added to the appropriate tubes. The tubes are mixed gently to ensure that the cells are in suspension and incubated at room temperature for 15-60 minutes. To each tube, 2.0 mLs of 1X PBS working solution is added. The tubes are mixed gently then centrifuged at 300×g for 5 minutes. The supernatant is aspirated,

leaving approximately 50 µl of fluid. The tubes are mixed thoroughly to ensure that the cells are in suspension.

[0073] The pellet is resuspended in an appropriate volume of fluid for flow cytometry analysis. The sample is analyzed on a flow cytometer within 24-48 hours. For analysis, the gate is on the monocyte population and the data is collected in list mode. Qualitative and or quantitative differences are determined between normal and MS patients using the analysis software. Optimization steps include varying incubation time with antibodies, fixation time and permeabilization time.

[0074] Although there has been shown and described the preferred embodiment of the present invention, it will be readily apparent to those skilled in the art that modifications may be made thereto which do not exceed the scope of the appended claims. Therefore, the scope of the invention is only to be limited by the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 80

<210> SEQ ID NO 1

<211> LENGTH: 758

<212> TYPE: PRT

<213> ORGANISM: Human

<400> SEQUENCE: 1

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1                               5                               10                               15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20                               25                               30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35                               40                               45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50                               55                               60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65                               70                               75                               80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85                               90                               95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100                              105                              110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
115                              120                              125
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
130                              135                              140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
145                              150                              155                              160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
165                              170                              175
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
180                              185                              190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
195                              200                              205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
210                              215                              220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala

```


-continued

Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val
645 650 655

Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly
660 665 670

Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn Lys Lys Ile
675 680 685

Glu Thr His Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala Lys Thr Asp
690 695 700

His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser Gly Asp Thr
705 710 715 720

Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser Ile Asp Met
725 730 735

Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Val Ser Ala Ser
740 745 750

Leu Ala Lys Gln Gly Leu
755

<210> SEQ ID NO 2
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 2

Met Ala Glu Pro Arg Gln Glu Phe Glu Val
1 5 10

<210> SEQ ID NO 3
 <211> LENGTH: 20
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 3

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1 5 10 15

Thr Tyr Gly Leu
20

<210> SEQ ID NO 4
 <211> LENGTH: 30
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 4

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr
20 25 30

<210> SEQ ID NO 5
 <211> LENGTH: 40
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 5

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His

-continued

20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp
 35 40

<210> SEQ ID NO 6
 <211> LENGTH: 50
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 6

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45

Gln Thr
 50

<210> SEQ ID NO 7
 <211> LENGTH: 60
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 7

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly
 50 55 60

<210> SEQ ID NO 8
 <211> LENGTH: 70
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 8

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60

Asp Ala Lys Ser Thr Pro
 65 70

<210> SEQ ID NO 9
 <211> LENGTH: 80
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 9

-continued

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1           5           10           15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
           20           25           30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
           35           40           45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
           50           55           60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65           70           75           80

```

```

<210> SEQ ID NO 10
<211> LENGTH: 90
<212> TYPE: PRT
<213> ORGANISM: Human

```

```

<400> SEQUENCE: 10

```

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1           5           10           15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
           20           25           30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
           35           40           45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
           50           55           60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65           70           75           80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala
           85           90

```

```

<210> SEQ ID NO 11
<211> LENGTH: 100
<212> TYPE: PRT
<213> ORGANISM: Human

```

```

<400> SEQUENCE: 11

```

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1           5           10           15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
           20           25           30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
           35           40           45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
           50           55           60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65           70           75           80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Gln Pro His Thr Glu
           85           90           95
Ile Pro Glu Gly
           100

```

```

<210> SEQ ID NO 12
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Human

```

-continued

<400> SEQUENCE: 12

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1           5           10           15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
           20           25           30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
           35           40           45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
           50           55           60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
           65           70           75           80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
           85           90           95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp
           100           105           110

```

<210> SEQ ID NO 13

<211> LENGTH: 120

<212> TYPE: PRT

<213> ORGANISM: Human

<400> SEQUENCE: 13

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1           5           10           15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
           20           25           30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
           35           40           45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
           50           55           60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
           65           70           75           80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
           85           90           95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
           100           105           110
Ser Leu Glu Asp Glu Ala Ala Gly
           115           120

```

<210> SEQ ID NO 14

<211> LENGTH: 130

<212> TYPE: PRT

<213> ORGANISM: Human

<400> SEQUENCE: 14

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1           5           10           15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
           20           25           30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
           35           40           45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
           50           55           60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val

```


-continued

100	105	110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser 115	120	125
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly 130	135	140
Leu Ser His Gln Leu Met 145	150	

<210> SEQ ID NO 17
 <211> LENGTH: 160
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 17

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly 1	5	10	15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His 20	25	30	
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu 35	40	45	
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser 50	55	60	
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val 65	70	75	80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu 85	90	95	
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro 100	105	110	
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser 115	120	125	
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly 130	135	140	
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro 145	150	155	160

<210> SEQ ID NO 18
 <211> LENGTH: 170
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 18

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly 1	5	10	15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His 20	25	30	
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu 35	40	45	
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser 50	55	60	
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val 65	70	75	80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu 85	90	95	
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro			

-continued

	100							105							110
Ser	Leu	Glu	Asp	Glu	Ala	Ala	Gly	His	Val	Thr	Gln	Glu	Pro	Glu	Ser
	115						120					125			
Gly	Lys	Val	Val	Gln	Glu	Gly	Phe	Leu	Arg	Glu	Pro	Gly	Pro	Pro	Gly
	130					135					140				
Leu	Ser	His	Gln	Leu	Met	Ser	Gly	Met	Pro	Gly	Ala	Pro	Leu	Leu	Pro
145					150					155					160
Glu	Gly	Pro	Arg	Glu	Ala	Thr	Arg	Gln	Pro						
				165				170							

<210> SEQ ID NO 19
 <211> LENGTH: 180
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 19

Met	Ala	Glu	Pro	Arg	Gln	Glu	Phe	Glu	Val	Met	Glu	Asp	His	Ala	Gly
1				5					10					15	
Thr	Tyr	Gly	Leu	Gly	Asp	Arg	Lys	Asp	Gln	Gly	Gly	Tyr	Thr	Met	His
			20					25					30		
Gln	Asp	Gln	Glu	Gly	Asp	Thr	Asp	Ala	Gly	Leu	Lys	Glu	Ser	Pro	Leu
		35					40					45			
Gln	Thr	Pro	Thr	Glu	Asp	Gly	Ser	Glu	Glu	Pro	Gly	Ser	Glu	Thr	Ser
		50				55					60				
Asp	Ala	Lys	Ser	Thr	Pro	Thr	Ala	Glu	Asp	Val	Thr	Ala	Pro	Leu	Val
65					70					75					80
Asp	Glu	Gly	Ala	Pro	Gly	Lys	Gln	Ala	Ala	Ala	Gln	Pro	His	Thr	Glu
				85					90					95	
Ile	Pro	Glu	Gly	Thr	Thr	Ala	Glu	Glu	Ala	Gly	Ile	Gly	Asp	Thr	Pro
			100						105				110		
Ser	Leu	Glu	Asp	Glu	Ala	Ala	Gly	His	Val	Thr	Gln	Glu	Pro	Glu	Ser
		115					120					125			
Gly	Lys	Val	Val	Gln	Glu	Gly	Phe	Leu	Arg	Glu	Pro	Gly	Pro	Pro	Gly
	130					135					140				
Leu	Ser	His	Gln	Leu	Met	Ser	Gly	Met	Pro	Gly	Ala	Pro	Leu	Leu	Pro
145					150					155					160
Glu	Gly	Pro	Arg	Glu	Ala	Thr	Arg	Gln	Pro	Ser	Gly	Thr	Gly	Pro	Glu
				165					170					175	
Asp	Thr	Glu	Gly												
			180												

<210> SEQ ID NO 20
 <211> LENGTH: 190
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 20

Met	Ala	Glu	Pro	Arg	Gln	Glu	Phe	Glu	Val	Met	Glu	Asp	His	Ala	Gly
1				5					10					15	
Thr	Tyr	Gly	Leu	Gly	Asp	Arg	Lys	Asp	Gln	Gly	Gly	Tyr	Thr	Met	His
			20					25					30		
Gln	Asp	Gln	Glu	Gly	Asp	Thr	Asp	Ala	Gly	Leu	Lys	Glu	Ser	Pro	Leu
		35					40					45			
Gln	Thr	Pro	Thr	Glu	Asp	Gly	Ser	Glu	Glu	Pro	Gly	Ser	Glu	Thr	Ser

-continued

```

<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 22

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1           5           10           15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20           25           30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35           40           45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50           55           60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65           70           75           80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85           90           95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100          105          110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
115          120          125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
130          135          140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
145          150          155          160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
165          170          175

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
180          185          190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
195          200          205

Lys Glu
210

```

```

<210> SEQ ID NO 23
<211> LENGTH: 220
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 23

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1           5           10           15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20           25           30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35           40           45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50           55           60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65           70           75           80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85           90           95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100          105          110

```

-continued

```

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115                               120           125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130                               135           140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145                               150           155           160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165                               170           175

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180                               185           190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195                               200           205

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu
 210                               215           220

```

```

<210> SEQ ID NO 24
<211> LENGTH: 230
<212> TYPE: PRT
<213> ORGANISM: Human

```

```

<400> SEQUENCE: 24

```

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1                               5           10           15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20                               25           30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35                               40           45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50                               55           60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65                               70           75           80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85                               90           95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100                              105          110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115                              120          125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130                              135          140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145                              150          155           160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165                              170          175

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180                              185          190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195                              200          205

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210                              215          220

Asp Glu Ser Ser Pro Gln
 225                              230

```

```

<210> SEQ ID NO 25

```

-continued

```

<211> LENGTH: 240
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 25
Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1          5          10          15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20          25          30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35          40          45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50          55          60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65          70          75          80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85          90          95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100         105         110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
115         120         125
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
130         135         140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
145         150         155         160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
165         170         175
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
180         185         190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
195         200         205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
210         215         220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
225         230         235         240

```

```

<210> SEQ ID NO 26
<211> LENGTH: 250
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 26
Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1          5          10          15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20          25          30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35          40          45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50          55          60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65          70          75          80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85          90          95

```

-continued

```

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
      100                               105                               110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
      115                               120
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
      130                               135                               140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
      145                               150                               155                               160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
      165                               170
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
      180                               185                               190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
      195                               200                               205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
      210                               215                               220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
      225                               230                               235                               240
Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala
      245                               250

```

```

<210> SEQ ID NO 27
<211> LENGTH: 260
<212> TYPE: PRT
<213> ORGANISM: Human

```

```

<400> SEQUENCE: 27

```

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
  1      5      10      15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
      20      25      30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
      35      40      45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
      50      55      60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
      65      70      75      80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
      85      90      95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
      100                               105                               110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
      115                               120
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
      130                               135                               140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
      145                               150                               155                               160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
      165                               170
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
      180                               185                               190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly

```

-continued

```

195          200          205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210          215          220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
225          230          235          240
Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245          250          255
Pro Gly Phe Pro
 260

```

```

<210> SEQ ID NO 28
<211> LENGTH: 270
<212> TYPE: PRT
<213> ORGANISM: Human

```

```

<400> SEQUENCE: 28

```

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1          5          10          15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20          25          30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35          40          45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50          55          60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65          70          75          80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85          90          95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100          105          110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115          120          125
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130          135          140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145          150          155          160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165          170          175
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180          185          190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195          200          205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210          215          220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225          230          235          240
Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245          250          255
Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp
 260          265          270

```

```

<210> SEQ ID NO 29
<211> LENGTH: 280

```

-continued

```

<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 29

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1           5           10           15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20           25           30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35           40           45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50           55           60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65           70           75           80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85           90           95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100          105          110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
115          120          125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
130          135          140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
145          150          155          160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
165          170          175

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
180          185          190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
195          200          205

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
210          215          220

Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
225          230          235          240

Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
245          250          255

Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
260          265          270

Ser Lys Val Ser Thr Glu Ile Pro
275          280

```

```

<210> SEQ ID NO 30
<211> LENGTH: 290
<212> TYPE: PRT
<213> ORGANISM: Human

```

```

<400> SEQUENCE: 30

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1           5           10           15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20           25           30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35           40           45

```

-continued

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125
 Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140
 Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly
 290

<210> SEQ ID NO 31
 <211> LENGTH: 300
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 31

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110

-continued

```

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210                215                220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225                230                235                240
Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
                245                250                255
Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
                260                265                270
Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
                275                280                285
Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290                295                300
Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305                310                315                320

```

```

<210> SEQ ID NO 34
<211> LENGTH: 330
<212> TYPE: PRT
<213> ORGANISM: Human

```

```

<400> SEQUENCE: 34

```

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1                5                10                15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
                20                25                30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35                40                45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50                55                60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65                70                75                80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85                90                95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100               105               110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115               120               125
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130               135               140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145               150               155               160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165               170               175
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180               185               190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195               200               205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210               215               220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225               230               235               240
Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245               250               255

```

-continued

Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285

Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300

Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320

His Leu Gly Arg Ala Ala Phe Pro Gly Ala
 325 330

<210> SEQ ID NO 35
 <211> LENGTH: 340
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 35

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220

Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240

Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255

Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser

-continued

```

                275                280                285
Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
  290                295                300

Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
  305                310                315                320

His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
  325                330                335

Ala Arg Gly Pro
  340
    
```

```

<210> SEQ ID NO 36
<211> LENGTH: 350
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 36
    
```

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
  1                5                10                15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
  20                25                30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
  35                40                45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
  50                55                60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
  65                70                75                80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
  85                90                95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
  100               105               110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
  115               120               125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
  130               135               140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
  145               150               155               160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
  165               170               175

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
  180               185               190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
  195               200               205

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
  210               215               220

Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
  225               230               235               240

Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
  245               250               255

Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
  260               265               270

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
  275               280               285
    
```

-continued

```

Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290                295                300
Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305                310                315                320
His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
                325                330                335
Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp
                340                345                350

```

```

<210> SEQ ID NO 37
<211> LENGTH: 360
<212> TYPE: PRT
<213> ORGANISM: Human

```

```

<400> SEQUENCE: 37

```

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1                5                10                15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
                20                25                30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
                35                40                45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50                55                60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65                70                75                80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
                85                90                95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
                100                105                110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
                115                120                125
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130                135                140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145                150                155                160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
                165                170                175
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
                180                185                190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195                200                205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210                215                220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225                230                235                240
Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
                245                250                255
Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
                260                265                270
Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
                275                280                285
Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290                295                300

```

-continued

Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala
 355 360

<210> SEQ ID NO 38
 <211> LENGTH: 370
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 38

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125
 Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140
 Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His

-continued

Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285

Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300

Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320

His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335

Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350

Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365

Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380

Gly Thr Gly Ser Asp Asp
 385 390

<210> SEQ ID NO 41
 <211> LENGTH: 400
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 41

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val

-continued

210				215				220							
Asp	Glu	Ser	Ser	Pro	Gln	Asp	Ser	Pro	Pro	Ser	Lys	Ala	Ser	Pro	Ala
225					230					235					240
Gln	Asp	Gly	Arg	Pro	Pro	Gln	Thr	Ala	Ala	Arg	Glu	Ala	Thr	Ser	Ile
				245					250					255	
Pro	Gly	Phe	Pro	Ala	Glu	Gly	Ala	Ile	Pro	Leu	Pro	Val	Asp	Phe	Leu
			260					265					270		
Ser	Lys	Val	Ser	Thr	Glu	Ile	Pro	Ala	Ser	Glu	Pro	Asp	Gly	Pro	Ser
	275						280					285			
Val	Gly	Arg	Ala	Lys	Gly	Gln	Asp	Ala	Pro	Leu	Glu	Phe	Thr	Phe	His
	290					295					300				
Val	Glu	Ile	Thr	Pro	Asn	Val	Gln	Lys	Glu	Gln	Ala	His	Ser	Glu	Glu
305					310					315					320
His	Leu	Gly	Arg	Ala	Ala	Phe	Pro	Gly	Ala	Pro	Gly	Glu	Gly	Pro	Glu
				325					330					335	
Ala	Arg	Gly	Pro	Ser	Leu	Gly	Glu	Asp	Thr	Lys	Glu	Ala	Asp	Leu	Pro
			340					345					350		
Glu	Pro	Ser	Glu	Lys	Gln	Pro	Ala	Ala	Ala	Pro	Arg	Gly	Lys	Pro	Val
		355					360					365			
Ser	Arg	Val	Pro	Gln	Leu	Lys	Ala	Arg	Met	Val	Ser	Lys	Ser	Lys	Asp
	370					375					380				
Gly	Thr	Gly	Ser	Asp	Asp	Lys	Lys	Ala	Lys	Thr	Ser	Thr	Arg	Ser	Ser
385					390					395					400

<210> SEQ ID NO 42
 <211> LENGTH: 410
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 42

Met	Ala	Glu	Pro	Arg	Gln	Glu	Phe	Glu	Val	Met	Glu	Asp	His	Ala	Gly
1				5					10					15	
Thr	Tyr	Gly	Leu	Gly	Asp	Arg	Lys	Asp	Gln	Gly	Gly	Tyr	Thr	Met	His
			20					25					30		
Gln	Asp	Gln	Glu	Gly	Asp	Thr	Asp	Ala	Gly	Leu	Lys	Glu	Ser	Pro	Leu
		35					40					45			
Gln	Thr	Pro	Thr	Glu	Asp	Gly	Ser	Glu	Glu	Pro	Gly	Ser	Glu	Thr	Ser
		50				55					60				
Asp	Ala	Lys	Ser	Thr	Pro	Thr	Ala	Glu	Asp	Val	Thr	Ala	Pro	Leu	Val
65				70					75					80	
Asp	Glu	Gly	Ala	Pro	Gly	Lys	Gln	Ala	Ala	Ala	Gln	Pro	His	Thr	Glu
			85					90					95		
Ile	Pro	Glu	Gly	Thr	Thr	Ala	Glu	Glu	Ala	Gly	Ile	Gly	Asp	Thr	Pro
		100						105					110		
Ser	Leu	Glu	Asp	Glu	Ala	Ala	Gly	His	Val	Thr	Gln	Glu	Pro	Glu	Ser
		115				120						125			
Gly	Lys	Val	Val	Gln	Glu	Gly	Phe	Leu	Arg	Glu	Pro	Gly	Pro	Pro	Gly
	130					135					140				
Leu	Ser	His	Gln	Leu	Met	Ser	Gly	Met	Pro	Gly	Ala	Pro	Leu	Leu	Pro
145				150						155					160
Glu	Gly	Pro	Arg	Glu	Ala	Thr	Arg	Gln	Pro	Ser	Gly	Thr	Gly	Pro	Glu
				165					170					175	

-continued

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400
 Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu
 405 410

<210> SEQ ID NO 43
 <211> LENGTH: 420
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 43

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125

-continued

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140
 Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400
 Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415
 Pro Gly Ser Ser
 420

<210> SEQ ID NO 44
 <211> LENGTH: 430
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 44

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser

-continued

50					55					60					
Asp	Ala	Lys	Ser	Thr	Pro	Thr	Ala	Glu	Asp	Val	Thr	Ala	Pro	Leu	Val
65					70					75					80
Asp	Glu	Gly	Ala	Pro	Gly	Lys	Gln	Ala	Ala	Ala	Gln	Pro	His	Thr	Glu
				85					90					95	
Ile	Pro	Glu	Gly	Thr	Thr	Ala	Glu	Glu	Ala	Gly	Ile	Gly	Asp	Thr	Pro
			100					105					110		
Ser	Leu	Glu	Asp	Glu	Ala	Ala	Gly	His	Val	Thr	Gln	Glu	Pro	Glu	Ser
		115					120					125			
Gly	Lys	Val	Val	Gln	Glu	Gly	Phe	Leu	Arg	Glu	Pro	Gly	Pro	Pro	Gly
	130					135					140				
Leu	Ser	His	Gln	Leu	Met	Ser	Gly	Met	Pro	Gly	Ala	Pro	Leu	Leu	Pro
	145					150					155				160
Glu	Gly	Pro	Arg	Glu	Ala	Thr	Arg	Gln	Pro	Ser	Gly	Thr	Gly	Pro	Glu
				165					170					175	
Asp	Thr	Glu	Gly	Gly	Arg	His	Ala	Pro	Glu	Leu	Leu	Lys	His	Gln	Leu
			180					185					190		
Leu	Gly	Asp	Leu	His	Gln	Glu	Gly	Pro	Pro	Leu	Lys	Gly	Ala	Gly	Gly
		195					200					205			
Lys	Glu	Arg	Pro	Gly	Ser	Lys	Glu	Glu	Val	Asp	Glu	Asp	Arg	Asp	Val
	210					215					220				
Asp	Glu	Ser	Ser	Pro	Gln	Asp	Ser	Pro	Pro	Ser	Lys	Ala	Ser	Pro	Ala
	225					230					235				240
Gln	Asp	Gly	Arg	Pro	Pro	Gln	Thr	Ala	Ala	Arg	Glu	Ala	Thr	Ser	Ile
				245					250					255	
Pro	Gly	Phe	Pro	Ala	Glu	Gly	Ala	Ile	Pro	Leu	Pro	Val	Asp	Phe	Leu
			260					265					270		
Ser	Lys	Val	Ser	Thr	Glu	Ile	Pro	Ala	Ser	Glu	Pro	Asp	Gly	Pro	Ser
		275					280					285			
Val	Gly	Arg	Ala	Lys	Gly	Gln	Asp	Ala	Pro	Leu	Glu	Phe	Thr	Phe	His
	290					295					300				
Val	Glu	Ile	Thr	Pro	Asn	Val	Gln	Lys	Glu	Gln	Ala	His	Ser	Glu	Glu
	305					310					315				320
His	Leu	Gly	Arg	Ala	Ala	Phe	Pro	Gly	Ala	Pro	Gly	Glu	Gly	Pro	Glu
				325					330					335	
Ala	Arg	Gly	Pro	Ser	Leu	Gly	Glu	Asp	Thr	Lys	Glu	Ala	Asp	Leu	Pro
			340					345					350		
Glu	Pro	Ser	Glu	Lys	Gln	Pro	Ala	Ala	Ala	Pro	Arg	Gly	Lys	Pro	Val
		355					360					365			
Ser	Arg	Val	Pro	Gln	Leu	Lys	Ala	Arg	Met	Val	Ser	Lys	Ser	Lys	Asp
		370				375					380				
Gly	Thr	Gly	Ser	Asp	Asp	Lys	Lys	Ala	Lys	Thr	Ser	Thr	Arg	Ser	Ser
	385					390					395				400
Ala	Lys	Thr	Leu	Lys	Asn	Arg	Pro	Cys	Leu	Ser	Pro	Lys	Leu	Pro	Thr
				405					410					415	
Pro	Gly	Ser	Ser	Asp	Pro	Leu	Ile	Gln	Pro	Ser	Ser	Pro	Ala		
			420					425					430		

<210> SEQ ID NO 45
 <211> LENGTH: 440
 <212> TYPE: PRT
 <213> ORGANISM: Human

-continued

<400> SEQUENCE: 45

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125
 Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140
 Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser

-continued

```

385                390                395                400
Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
      405                410                415
Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
      420                425                430
Pro Glu Pro Pro Ser Ser Pro Lys
      435                440

```

```

<210> SEQ ID NO 46
<211> LENGTH: 450
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 46

```

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1      5      10      15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20      25      30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35      40      45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50      55      60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65      70      75      80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85      90      95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100     105     110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115     120     125
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130     135     140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145     150     155     160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165     170     175
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180     185     190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195     200     205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210     215     220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225     230     235     240
Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245     250     255
Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260     265     270
Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275     280     285
Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290     295     300

```

-continued

Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400
 Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415
 Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430
 Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445
 Thr Gly
 450

<210> SEQ ID NO 47
 <211> LENGTH: 460
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 47

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125
 Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140
 Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205

-continued

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400
 Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415
 Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430
 Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445
 Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys
 450 455 460

<210> SEQ ID NO 48
 <211> LENGTH: 470
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 48

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro

-continued

100				105				110							
Ser	Leu	Glu	Asp	Glu	Ala	Ala	Gly	His	Val	Thr	Gln	Glu	Pro	Glu	Ser
	115						120						125		
Gly	Lys	Val	Val	Gln	Glu	Gly	Phe	Leu	Arg	Glu	Pro	Gly	Pro	Pro	Gly
	130						135						140		
Leu	Ser	His	Gln	Leu	Met	Ser	Gly	Met	Pro	Gly	Ala	Pro	Leu	Leu	Pro
	145				150						155				160
Glu	Gly	Pro	Arg	Glu	Ala	Thr	Arg	Gln	Pro	Ser	Gly	Thr	Gly	Pro	Glu
					165						170				175
Asp	Thr	Glu	Gly	Arg	His	Ala	Pro	Glu	Leu	Leu	Lys	His	Gln	Leu	
					180						185				190
Leu	Gly	Asp	Leu	His	Gln	Glu	Gly	Pro	Pro	Leu	Lys	Gly	Ala	Gly	Gly
													205		
Lys	Glu	Arg	Pro	Gly	Ser	Lys	Glu	Glu	Val	Asp	Glu	Asp	Arg	Asp	Val
	210						215						220		
Asp	Glu	Ser	Ser	Pro	Gln	Asp	Ser	Pro	Pro	Ser	Lys	Ala	Ser	Pro	Ala
	225				230						235				240
Gln	Asp	Gly	Arg	Pro	Pro	Gln	Thr	Ala	Ala	Arg	Glu	Ala	Thr	Ser	Ile
					245						250				255
Pro	Gly	Phe	Pro	Ala	Glu	Gly	Ala	Ile	Pro	Leu	Pro	Val	Asp	Phe	Leu
					260										270
Ser	Lys	Val	Ser	Thr	Glu	Ile	Pro	Ala	Ser	Glu	Pro	Asp	Gly	Pro	Ser
													285		
Val	Gly	Arg	Ala	Lys	Gly	Gln	Asp	Ala	Pro	Leu	Glu	Phe	Thr	Phe	His
Val	Glu	Ile	Thr	Pro	Asn	Val	Gln	Lys	Glu	Gln	Ala	His	Ser	Glu	Glu
	305				310						315				320
His	Leu	Gly	Arg	Ala	Ala	Phe	Pro	Gly	Ala	Pro	Gly	Glu	Gly	Pro	Glu
					325						330				335
Ala	Arg	Gly	Pro	Ser	Leu	Gly	Glu	Asp	Thr	Lys	Glu	Ala	Asp	Leu	Pro
													350		
Glu	Pro	Ser	Glu	Lys	Gln	Pro	Ala	Ala	Ala	Pro	Arg	Gly	Lys	Pro	Val
							360						365		
Ser	Arg	Val	Pro	Gln	Leu	Lys	Ala	Arg	Met	Val	Ser	Lys	Ser	Lys	Asp
	370						375								
Gly	Thr	Gly	Ser	Asp	Asp	Lys	Lys	Ala	Lys	Thr	Ser	Thr	Arg	Ser	Ser
	385				390						395				400
Ala	Lys	Thr	Leu	Lys	Asn	Arg	Pro	Cys	Leu	Ser	Pro	Lys	Leu	Pro	Thr
					405										415
Pro	Gly	Ser	Ser	Asp	Pro	Leu	Ile	Gln	Pro	Ser	Ser	Pro	Ala	Val	Cys
													430		
Pro	Glu	Pro	Pro	Ser	Ser	Pro	Lys	His	Val	Ser	Ser	Val	Thr	Ser	Arg
							440						445		
Thr	Gly	Ser	Ser	Gly	Ala	Lys	Glu	Met	Lys	Leu	Lys	Gly	Ala	Asp	Gly
	450						455								460
Lys	Thr	Lys	Ile	Ala	Thr										
	465				470										

<210> SEQ ID NO 49
 <211> LENGTH: 480
 <212> TYPE: PRT
 <213> ORGANISM: Human

-continued

<400> SEQUENCE: 49

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125
 Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140
 Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser

-continued

```

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
  275                               280                               285

Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
  290                               295                               300

Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
  305                               310                               315                               320

His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
  325                               330                               335

Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
  340                               345                               350

Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
  355                               360                               365

Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
  370                               375                               380

Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
  385                               390                               395                               400

Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
  405                               410                               415

Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
  420                               425                               430

Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
  435                               440                               445

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
  450                               455                               460

Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
  465                               470                               475                               480

Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala
  485                               490

```

```

<210> SEQ ID NO 51
<211> LENGTH: 500
<212> TYPE: PRT
<213> ORGANISM: Human

```

```

<400> SEQUENCE: 51

```

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
  1      5      10      15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
  20     25     30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
  35     40     45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
  50     55     60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
  65     70     75     80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
  85     90     95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
  100    105    110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
  115    120    125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
  130    135    140

```

-continued

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400
 Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415
 Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430
 Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445
 Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460
 Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480
 Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495
 Lys Thr Pro Pro
 500

<210> SEQ ID NO 52
 <211> LENGTH: 510
 <212> TYPE: PRT
 <213> ORGANISM: Human

-continued

<400> SEQUENCE: 52

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1      5      10      15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20      25      30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35      40      45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50      55      60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65      70      75      80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Gln Pro His Thr Glu
85      90      95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100     105     110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
115     120     125
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
130     135     140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
145     150     155     160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
165     170     175
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
180     185     190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
195     200     205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
210     215     220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
225     230     235     240
Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
245     250     255
Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
260     265     270
Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
275     280     285
Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
290     295     300
Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
305     310     315     320
His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
325     330     335
Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
340     345     350
Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
355     360     365
Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
370     375     380
Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
385     390     395     400

```

-continued

Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
405 410 415
Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
420 425 430
Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
435 440 445
Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
450 455 460
Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
465 470 475 480
Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
485 490 495
Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp
500 505 510

<210> SEQ ID NO 53
<211> LENGTH: 520
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 53

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1 5 10 15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20 25 30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35 40 45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50 55 60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65 70 75 80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Gln Pro His Thr Glu
85 90 95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100 105 110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
115 120 125
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
130 135 140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
145 150 155 160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
165 170 175
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
180 185 190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
195 200 205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
210 215 220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
225 230 235 240
Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile

-continued

Asp	Glu	Gly	Ala	Pro	Gly	Lys	Gln	Ala	Ala	Ala	Gln	Pro	His	Thr	Glu
				85						90				95	
Ile	Pro	Glu	Gly	Thr	Thr	Ala	Glu	Glu	Ala	Gly	Ile	Gly	Asp	Thr	Pro
			100						105				110		
Ser	Leu	Glu	Asp	Glu	Ala	Ala	Gly	His	Val	Thr	Gln	Glu	Pro	Glu	Ser
		115					120					125			
Gly	Lys	Val	Val	Gln	Glu	Gly	Phe	Leu	Arg	Glu	Pro	Gly	Pro	Pro	Gly
	130					135					140				
Leu	Ser	His	Gln	Leu	Met	Ser	Gly	Met	Pro	Gly	Ala	Pro	Leu	Leu	Pro
145					150					155					160
Glu	Gly	Pro	Arg	Glu	Ala	Thr	Arg	Gln	Pro	Ser	Gly	Thr	Gly	Pro	Glu
				165					170					175	
Asp	Thr	Glu	Gly	Gly	Arg	His	Ala	Pro	Glu	Leu	Leu	Lys	His	Gln	Leu
			180					185						190	
Leu	Gly	Asp	Leu	His	Gln	Glu	Gly	Pro	Pro	Leu	Lys	Gly	Ala	Gly	Gly
		195					200					205			
Lys	Glu	Arg	Pro	Gly	Ser	Lys	Glu	Glu	Val	Asp	Glu	Asp	Arg	Asp	Val
	210					215					220				
Asp	Glu	Ser	Ser	Pro	Gln	Asp	Ser	Pro	Pro	Ser	Lys	Ala	Ser	Pro	Ala
225					230					235					240
Gln	Asp	Gly	Arg	Pro	Pro	Gln	Thr	Ala	Ala	Arg	Glu	Ala	Thr	Ser	Ile
				245					250					255	
Pro	Gly	Phe	Pro	Ala	Glu	Gly	Ala	Ile	Pro	Leu	Pro	Val	Asp	Phe	Leu
			260					265						270	
Ser	Lys	Val	Ser	Thr	Glu	Ile	Pro	Ala	Ser	Glu	Pro	Asp	Gly	Pro	Ser
		275					280					285			
Val	Gly	Arg	Ala	Lys	Gly	Gln	Asp	Ala	Pro	Leu	Glu	Phe	Thr	Phe	His
	290					295					300				
Val	Glu	Ile	Thr	Pro	Asn	Val	Gln	Lys	Glu	Gln	Ala	His	Ser	Glu	Glu
305					310						315				320
His	Leu	Gly	Arg	Ala	Ala	Phe	Pro	Gly	Ala	Pro	Gly	Glu	Gly	Pro	Glu
				325					330					335	
Ala	Arg	Gly	Pro	Ser	Leu	Gly	Glu	Asp	Thr	Lys	Glu	Ala	Asp	Leu	Pro
			340					345						350	
Glu	Pro	Ser	Glu	Lys	Gln	Pro	Ala	Ala	Ala	Pro	Arg	Gly	Lys	Pro	Val
		355					360					365			
Ser	Arg	Val	Pro	Gln	Leu	Lys	Ala	Arg	Met	Val	Ser	Lys	Ser	Lys	Asp
	370					375						380			
Gly	Thr	Gly	Ser	Asp	Asp	Lys	Lys	Ala	Lys	Thr	Ser	Thr	Arg	Ser	Ser
385					390					395					400
Ala	Lys	Thr	Leu	Lys	Asn	Arg	Pro	Cys	Leu	Ser	Pro	Lys	Leu	Pro	Thr
			405						410					415	
Pro	Gly	Ser	Ser	Asp	Pro	Leu	Ile	Gln	Pro	Ser	Ser	Pro	Ala	Val	Cys
			420					425					430		
Pro	Glu	Pro	Pro	Ser	Ser	Pro	Lys	His	Val	Ser	Ser	Val	Thr	Ser	Arg
		435					440					445			
Thr	Gly	Ser	Ser	Gly	Ala	Lys	Glu	Met	Lys	Leu	Lys	Gly	Ala	Asp	Gly
	450					455						460			
Lys	Thr	Lys	Ile	Ala	Thr	Pro	Arg	Gly	Ala	Ala	Pro	Pro	Gly	Gln	Lys
465					470					475					480
Gly	Gln	Ala	Asn	Ala	Thr	Arg	Ile	Pro	Ala	Lys	Thr	Pro	Pro	Ala	Pro

-continued

Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320

His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335

Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350

Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365

Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380

Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400

Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415

Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430

Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460

Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480

Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495

Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510

Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525

Thr Pro Ser Leu Pro Thr Pro Thr Arg Glu Pro
 530 535 540

<210> SEQ ID NO 56
 <211> LENGTH: 550
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 56

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125

-continued

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220

Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240

Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255

Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285

Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300

Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320

His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335

Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350

Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365

Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380

Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400

Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415

Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430

Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460

Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480

Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495

Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510

Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525

-continued

 Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540

 Val Val Arg Thr Pro Pro
 545 550

 <210> SEQ ID NO 57
 <211> LENGTH: 560
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 57

 Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125
 Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140
 Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335

-continued

Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350

Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365

Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380

Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400

Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415

Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430

Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460

Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480

Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495

Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510

Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525

Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540

Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
 545 550 555 560

<210> SEQ ID NO 58
 <211> LENGTH: 570
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 58

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly

-continued

130			135			140									
Leu	Ser	His	Gln	Leu	Met	Ser	Gly	Met	Pro	Gly	Ala	Pro	Leu	Leu	Pro
145					150					155					160
Glu	Gly	Pro	Arg	Glu	Ala	Thr	Arg	Gln	Pro	Ser	Gly	Thr	Gly	Pro	Glu
				165					170					175	
Asp	Thr	Glu	Gly	Gly	Arg	His	Ala	Pro	Glu	Leu	Leu	Lys	His	Gln	Leu
			180					185					190		
Leu	Gly	Asp	Leu	His	Gln	Glu	Gly	Pro	Pro	Leu	Lys	Gly	Ala	Gly	Gly
	195						200					205			
Lys	Glu	Arg	Pro	Gly	Ser	Lys	Glu	Glu	Val	Asp	Glu	Asp	Arg	Asp	Val
	210					215					220				
Asp	Glu	Ser	Ser	Pro	Gln	Asp	Ser	Pro	Pro	Ser	Lys	Ala	Ser	Pro	Ala
	225				230						235				240
Gln	Asp	Gly	Arg	Pro	Pro	Gln	Thr	Ala	Ala	Arg	Glu	Ala	Thr	Ser	Ile
				245					250					255	
Pro	Gly	Phe	Pro	Ala	Glu	Gly	Ala	Ile	Pro	Leu	Pro	Val	Asp	Phe	Leu
			260					265					270		
Ser	Lys	Val	Ser	Thr	Glu	Ile	Pro	Ala	Ser	Glu	Pro	Asp	Gly	Pro	Ser
		275					280					285			
Val	Gly	Arg	Ala	Lys	Gly	Gln	Asp	Ala	Pro	Leu	Glu	Phe	Thr	Phe	His
	290					295					300				
Val	Glu	Ile	Thr	Pro	Asn	Val	Gln	Lys	Glu	Gln	Ala	His	Ser	Glu	Glu
	305				310					315					320
His	Leu	Gly	Arg	Ala	Ala	Phe	Pro	Gly	Ala	Pro	Gly	Glu	Gly	Pro	Glu
				325					330					335	
Ala	Arg	Gly	Pro	Ser	Leu	Gly	Glu	Asp	Thr	Lys	Glu	Ala	Asp	Leu	Pro
			340					345					350		
Glu	Pro	Ser	Glu	Lys	Gln	Pro	Ala	Ala	Ala	Pro	Arg	Gly	Lys	Pro	Val
		355					360					365			
Ser	Arg	Val	Pro	Gln	Leu	Lys	Ala	Arg	Met	Val	Ser	Lys	Ser	Lys	Asp
	370					375					380				
Gly	Thr	Gly	Ser	Asp	Asp	Lys	Lys	Ala	Lys	Thr	Ser	Thr	Arg	Ser	Ser
	385				390					395					400
Ala	Lys	Thr	Leu	Lys	Asn	Arg	Pro	Cys	Leu	Ser	Pro	Lys	Leu	Pro	Thr
			405					410						415	
Pro	Gly	Ser	Ser	Asp	Pro	Leu	Ile	Gln	Pro	Ser	Ser	Pro	Ala	Val	Cys
			420					425					430		
Pro	Glu	Pro	Pro	Ser	Ser	Pro	Lys	His	Val	Ser	Ser	Val	Thr	Ser	Arg
		435					440					445			
Thr	Gly	Ser	Ser	Gly	Ala	Lys	Glu	Met	Lys	Leu	Lys	Gly	Ala	Asp	Gly
	450					455					460				
Lys	Thr	Lys	Ile	Ala	Thr	Pro	Arg	Gly	Ala	Ala	Pro	Pro	Gly	Gln	Lys
	465				470					475					480
Gly	Gln	Ala	Asn	Ala	Thr	Arg	Ile	Pro	Ala	Lys	Thr	Pro	Pro	Ala	Pro
				485					490					495	
Lys	Thr	Pro	Pro	Ser	Ser	Gly	Glu	Pro	Pro	Lys	Ser	Gly	Asp	Arg	Ser
			500					505					510		
Gly	Tyr	Ser	Ser	Pro	Gly	Ser	Pro	Gly	Thr	Pro	Gly	Ser	Arg	Ser	Arg
		515					520					525			
Thr	Pro	Ser	Leu	Pro	Thr	Pro	Pro	Thr	Arg	Glu	Pro	Lys	Lys	Val	Ala
	530					535					540				

-continued

Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
545 550 555 560

Gln Thr Ala Pro Val Pro Met Pro Asp Leu
565 570

<210> SEQ ID NO 59
<211> LENGTH: 580
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 59

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35 40 45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50 55 60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65 70 75 80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85 90 95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100 105 110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
115 120 125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
130 135 140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
145 150 155 160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
165 170 175

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
180 185 190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
195 200 205

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
210 215 220

Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
225 230 235 240

Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
245 250 255

Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
260 265 270

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
275 280 285

Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
290 295 300

Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
305 310 315 320

His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu

-continued

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125
 Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140
 Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400
 Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415
 Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430
 Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445
 Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460
 Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480
 Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495
 Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser

-continued

	500							505										510
Gly	Tyr	Ser	Ser	Pro	Gly	Ser	Pro	Gly	Thr	Pro	Gly	Ser	Arg	Ser	Arg			
	515						520					525						
Thr	Pro	Ser	Leu	Pro	Thr	Pro	Pro	Thr	Arg	Glu	Pro	Lys	Lys	Val	Ala			
	530					535					540							
Val	Val	Arg	Thr	Pro	Pro	Lys	Ser	Pro	Ser	Ser	Ala	Lys	Ser	Arg	Leu			
545				550						555					560			
Gln	Thr	Ala	Pro	Val	Pro	Met	Pro	Asp	Leu	Lys	Asn	Val	Lys	Ser	Lys			
			565					570							575			
Ile	Gly	Ser	Thr	Glu	Asn	Leu	Lys	His	Gln	Pro	Gly	Gly	Gly					
			580					585						590				

<210> SEQ ID NO 61
 <211> LENGTH: 600
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 61

Met	Ala	Glu	Pro	Arg	Gln	Glu	Phe	Glu	Val	Met	Glu	Asp	His	Ala	Gly
1			5						10					15	
Thr	Tyr	Gly	Leu	Gly	Asp	Arg	Lys	Asp	Gln	Gly	Gly	Tyr	Thr	Met	His
			20					25					30		
Gln	Asp	Gln	Glu	Gly	Asp	Thr	Asp	Ala	Gly	Leu	Lys	Glu	Ser	Pro	Leu
		35					40					45			
Gln	Thr	Pro	Thr	Glu	Asp	Gly	Ser	Glu	Glu	Pro	Gly	Ser	Glu	Thr	Ser
		50				55					60				
Asp	Ala	Lys	Ser	Thr	Pro	Thr	Ala	Glu	Asp	Val	Thr	Ala	Pro	Leu	Val
65					70					75					80
Asp	Glu	Gly	Ala	Pro	Gly	Lys	Gln	Ala	Ala	Ala	Gln	Pro	His	Thr	Glu
				85					90					95	
Ile	Pro	Glu	Gly	Thr	Thr	Ala	Glu	Glu	Ala	Gly	Ile	Gly	Asp	Thr	Pro
			100					105						110	
Ser	Leu	Glu	Asp	Glu	Ala	Ala	Gly	His	Val	Thr	Gln	Glu	Pro	Glu	Ser
		115					120						125		
Gly	Lys	Val	Val	Gln	Glu	Gly	Phe	Leu	Arg	Glu	Pro	Gly	Pro	Pro	Gly
		130				135					140				
Leu	Ser	His	Gln	Leu	Met	Ser	Gly	Met	Pro	Gly	Ala	Pro	Leu	Leu	Pro
145					150					155					160
Glu	Gly	Pro	Arg	Glu	Ala	Thr	Arg	Gln	Pro	Ser	Gly	Thr	Gly	Pro	Glu
			165						170					175	
Asp	Thr	Glu	Gly	Gly	Arg	His	Ala	Pro	Glu	Leu	Leu	Lys	His	Gln	Leu
			180					185						190	
Leu	Gly	Asp	Leu	His	Gln	Glu	Gly	Pro	Pro	Leu	Lys	Gly	Ala	Gly	Gly
		195					200					205			
Lys	Glu	Arg	Pro	Gly	Ser	Lys	Glu	Glu	Val	Asp	Glu	Asp	Arg	Asp	Val
		210				215					220				
Asp	Glu	Ser	Ser	Pro	Gln	Asp	Ser	Pro	Pro	Ser	Lys	Ala	Ser	Pro	Ala
225					230						235				240
Gln	Asp	Gly	Arg	Pro	Pro	Gln	Thr	Ala	Ala	Arg	Glu	Ala	Thr	Ser	Ile
				245					250					255	
Pro	Gly	Phe	Pro	Ala	Glu	Gly	Ala	Ile	Pro	Leu	Pro	Val	Asp	Phe	Leu
			260					265						270	

-continued

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400
 Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415
 Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430
 Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445
 Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460
 Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480
 Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495
 Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510
 Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525
 Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540
 Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
 545 550 555 560
 Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 565 570 575
 Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 580 585 590
 Gln Ile Ile Asn Lys Lys Leu Asp
 595 600

<210> SEQ ID NO 62
 <211> LENGTH: 610
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 62

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30

-continued

Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460

Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480

Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495

Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510

Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525

Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540

Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
 545 550 555 560

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 565 570 575

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 580 585 590

Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
 595 600 605

Gly Ser
 610

<210> SEQ ID NO 63
 <211> LENGTH: 620
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 63

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175

-continued

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220

Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240

Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255

Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285

Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300

Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320

His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335

Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350

Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365

Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380

Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400

Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415

Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430

Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460

Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480

Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495

Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510

Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525

Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540

Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
 545 550 555 560

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 565 570 575

-continued

```

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
      580                               585           590
Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
      595                               600           605
Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly
      610                               615           620

```

```

<210> SEQ ID NO 64
<211> LENGTH: 630
<212> TYPE: PRT
<213> ORGANISM: Human

```

```

<400> SEQUENCE: 64

```

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1      5      10      15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20      25      30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35      40      45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50      55      60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65      70      75      80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85      90      95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100     105     110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115     120     125
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130     135     140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145     150     155     160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165     170     175
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180     185     190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195     200     205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210     215     220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225     230     235     240
Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245     250     255
Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260     265     270
Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275     280     285
Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290     295     300
Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305     310     315     320

```

-continued

His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335

Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350

Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365

Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380

Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400

Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415

Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430

Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460

Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480

Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495

Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510

Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525

Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540

Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
 545 550 555 560

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 565 570 575

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 580 585 590

Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
 595 600 605

Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser Val Gln
 610 615 620

Ile Val Tyr Lys Pro Val
 625 630

<210> SEQ ID NO 65
 <211> LENGTH: 640
 <212> TYPE: PRT
 <213> ORGANISM: Human
 <400> SEQUENCE: 65

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu

-continued

35					40					45					
Gln	Thr	Pro	Thr	Glu	Asp	Gly	Ser	Glu	Glu	Pro	Gly	Ser	Glu	Thr	Ser
50					55					60					
Asp	Ala	Lys	Ser	Thr	Pro	Thr	Ala	Glu	Asp	Val	Thr	Ala	Pro	Leu	Val
65					70					75					80
Asp	Glu	Gly	Ala	Pro	Gly	Lys	Gln	Ala	Ala	Ala	Gln	Pro	His	Thr	Glu
				85					90					95	
Ile	Pro	Glu	Gly	Thr	Thr	Ala	Glu	Glu	Ala	Gly	Ile	Gly	Asp	Thr	Pro
			100						105					110	
Ser	Leu	Glu	Asp	Glu	Ala	Ala	Gly	His	Val	Thr	Gln	Glu	Pro	Glu	Ser
			115					120					125		
Gly	Lys	Val	Val	Gln	Glu	Gly	Phe	Leu	Arg	Glu	Pro	Gly	Pro	Pro	Gly
	130					135					140				
Leu	Ser	His	Gln	Leu	Met	Ser	Gly	Met	Pro	Gly	Ala	Pro	Leu	Leu	Pro
145					150					155					160
Glu	Gly	Pro	Arg	Glu	Ala	Thr	Arg	Gln	Pro	Ser	Gly	Thr	Gly	Pro	Glu
				165					170					175	
Asp	Thr	Glu	Gly	Gly	Arg	His	Ala	Pro	Glu	Leu	Leu	Lys	His	Gln	Leu
			180						185					190	
Leu	Gly	Asp	Leu	His	Gln	Glu	Gly	Pro	Pro	Leu	Lys	Gly	Ala	Gly	Gly
		195					200					205			
Lys	Glu	Arg	Pro	Gly	Ser	Lys	Glu	Glu	Val	Asp	Glu	Asp	Arg	Asp	Val
	210					215					220				
Asp	Glu	Ser	Ser	Pro	Gln	Asp	Ser	Pro	Pro	Ser	Lys	Ala	Ser	Pro	Ala
225					230					235					240
Gln	Asp	Gly	Arg	Pro	Pro	Gln	Thr	Ala	Ala	Arg	Glu	Ala	Thr	Ser	Ile
				245					250					255	
Pro	Gly	Phe	Pro	Ala	Glu	Gly	Ala	Ile	Pro	Leu	Pro	Val	Asp	Phe	Leu
			260					265						270	
Ser	Lys	Val	Ser	Thr	Glu	Ile	Pro	Ala	Ser	Glu	Pro	Asp	Gly	Pro	Ser
		275					280					285			
Val	Gly	Arg	Ala	Lys	Gly	Gln	Asp	Ala	Pro	Leu	Glu	Phe	Thr	Phe	His
						295					300				
Val	Glu	Ile	Thr	Pro	Asn	Val	Gln	Lys	Glu	Gln	Ala	His	Ser	Glu	Glu
305					310					315					320
His	Leu	Gly	Arg	Ala	Ala	Phe	Pro	Gly	Ala	Pro	Gly	Glu	Gly	Pro	Glu
				325					330					335	
Ala	Arg	Gly	Pro	Ser	Leu	Gly	Glu	Asp	Thr	Lys	Glu	Ala	Asp	Leu	Pro
			340					345					350		
Glu	Pro	Ser	Glu	Lys	Gln	Pro	Ala	Ala	Ala	Pro	Arg	Gly	Lys	Pro	Val
		355					360					365			
Ser	Arg	Val	Pro	Gln	Leu	Lys	Ala	Arg	Met	Val	Ser	Lys	Ser	Lys	Asp
	370					375					380				
Gly	Thr	Gly	Ser	Asp	Asp	Lys	Lys	Ala	Lys	Thr	Ser	Thr	Arg	Ser	Ser
385					390					395					400
Ala	Lys	Thr	Leu	Lys	Asn	Arg	Pro	Cys	Leu	Ser	Pro	Lys	Leu	Pro	Thr
				405					410					415	
Pro	Gly	Ser	Ser	Asp	Pro	Leu	Ile	Gln	Pro	Ser	Ser	Pro	Ala	Val	Cys
			420					425					430		
Pro	Glu	Pro	Pro	Ser	Ser	Pro	Lys	His	Val	Ser	Ser	Val	Thr	Ser	Arg
		435					440					445			

-continued

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460
 Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480
 Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495
 Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510
 Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525
 Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540
 Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
 545 550 555 560
 Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 565 570 575
 Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 580 585 590
 Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
 595 600 605
 Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser Val Gln
 610 615 620
 Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly
 625 630 635 640

<210> SEQ ID NO 66
 <211> LENGTH: 650
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 66

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125
 Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140
 Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu

-continued

165					170					175					
Asp	Thr	Glu	Gly	Gly	Arg	His	Ala	Pro	Glu	Leu	Leu	Lys	His	Gln	Leu
			180					185					190		
Leu	Gly	Asp	Leu	His	Gln	Glu	Gly	Pro	Pro	Leu	Lys	Gly	Ala	Gly	Gly
		195					200					205			
Lys	Glu	Arg	Pro	Gly	Ser	Lys	Glu	Glu	Val	Asp	Glu	Asp	Arg	Asp	Val
		210				215					220				
Asp	Glu	Ser	Ser	Pro	Gln	Asp	Ser	Pro	Pro	Ser	Lys	Ala	Ser	Pro	Ala
					230						235				240
Gln	Asp	Gly	Arg	Pro	Gln	Thr	Ala	Ala	Arg	Glu	Ala	Thr	Ser	Ile	
				245					250					255	
Pro	Gly	Phe	Pro	Ala	Glu	Gly	Ala	Ile	Pro	Leu	Pro	Val	Asp	Phe	Leu
			260					265						270	
Ser	Lys	Val	Ser	Thr	Glu	Ile	Pro	Ala	Ser	Glu	Pro	Asp	Gly	Pro	Ser
		275					280					285			
Val	Gly	Arg	Ala	Lys	Gly	Gln	Asp	Ala	Pro	Leu	Glu	Phe	Thr	Phe	His
		290				295						300			
Val	Glu	Ile	Thr	Pro	Asn	Val	Gln	Lys	Glu	Gln	Ala	His	Ser	Glu	Glu
					310						315				320
His	Leu	Gly	Arg	Ala	Ala	Phe	Pro	Gly	Ala	Pro	Gly	Glu	Gly	Pro	Glu
				325					330					335	
Ala	Arg	Gly	Pro	Ser	Leu	Gly	Glu	Asp	Thr	Lys	Glu	Ala	Asp	Leu	Pro
				340				345						350	
Glu	Pro	Ser	Glu	Lys	Gln	Pro	Ala	Ala	Ala	Pro	Arg	Gly	Lys	Pro	Val
		355					360					365			
Ser	Arg	Val	Pro	Gln	Leu	Lys	Ala	Arg	Met	Val	Ser	Lys	Ser	Lys	Asp
		370				375					380				
Gly	Thr	Gly	Ser	Asp	Asp	Lys	Lys	Ala	Lys	Thr	Ser	Thr	Arg	Ser	Ser
					390					395					400
Ala	Lys	Thr	Leu	Lys	Asn	Arg	Pro	Cys	Leu	Ser	Pro	Lys	Leu	Pro	Thr
				405					410					415	
Pro	Gly	Ser	Ser	Asp	Pro	Leu	Ile	Gln	Pro	Ser	Ser	Pro	Ala	Val	Cys
			420					425					430		
Pro	Glu	Pro	Pro	Ser	Ser	Pro	Lys	His	Val	Ser	Ser	Val	Thr	Ser	Arg
			435				440					445			
Thr	Gly	Ser	Ser	Gly	Ala	Lys	Glu	Met	Lys	Leu	Lys	Gly	Ala	Asp	Gly
				450		455					460				
Lys	Thr	Lys	Ile	Ala	Thr	Pro	Arg	Gly	Ala	Ala	Pro	Pro	Gly	Gln	Lys
					470					475					480
Gly	Gln	Ala	Asn	Ala	Thr	Arg	Ile	Pro	Ala	Lys	Thr	Pro	Pro	Ala	Pro
				485					490					495	
Lys	Thr	Pro	Pro	Ser	Ser	Gly	Glu	Pro	Pro	Lys	Ser	Gly	Asp	Arg	Ser
			500					505						510	
Gly	Tyr	Ser	Ser	Pro	Gly	Ser	Pro	Gly	Thr	Pro	Gly	Ser	Arg	Ser	Arg
			515				520						525		
Thr	Pro	Ser	Leu	Pro	Thr	Pro	Pro	Thr	Arg	Glu	Pro	Lys	Lys	Val	Ala
						535						540			
Val	Val	Arg	Thr	Pro	Pro	Lys	Ser	Pro	Ser	Ser	Ala	Lys	Ser	Arg	Leu
					550					555					560
Gln	Thr	Ala	Pro	Val	Pro	Met	Pro	Asp	Leu	Lys	Asn	Val	Lys	Ser	Lys
				565					570						575

-continued

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
580 585 590

Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
595 600 605

Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser Val Gln
610 615 620

Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly
625 630 635 640

Ser Leu Gly Asn Ile His His Lys Pro Gly
645 650

<210> SEQ ID NO 67
<211> LENGTH: 660
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 67

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1 5 10 15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35 40 45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50 55 60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65 70 75 80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85 90 95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100 105 110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
115 120 125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
130 135 140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
145 150 155 160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
165 170 175

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
180 185 190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
195 200 205

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
210 215 220

Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
225 230 235 240

Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
245 250 255

Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
260 265 270

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser

-continued

275				280				285							
Val	Gly	Arg	Ala	Lys	Gly	Gln	Asp	Ala	Pro	Leu	Glu	Phe	Thr	Phe	His
290						295					300				
Val	Glu	Ile	Thr	Pro	Asn	Val	Gln	Lys	Glu	Gln	Ala	His	Ser	Glu	Glu
305					310					315					320
His	Leu	Gly	Arg	Ala	Ala	Phe	Pro	Gly	Ala	Pro	Gly	Glu	Gly	Pro	Glu
				325					330					335	
Ala	Arg	Gly	Pro	Ser	Leu	Gly	Glu	Asp	Thr	Lys	Glu	Ala	Asp	Leu	Pro
				340					345					350	
Glu	Pro	Ser	Glu	Lys	Gln	Pro	Ala	Ala	Ala	Pro	Arg	Gly	Lys	Pro	Val
				355					360				365		
Ser	Arg	Val	Pro	Gln	Leu	Lys	Ala	Arg	Met	Val	Ser	Lys	Ser	Lys	Asp
				370		375					380				
Gly	Thr	Gly	Ser	Asp	Asp	Lys	Lys	Ala	Lys	Thr	Ser	Thr	Arg	Ser	Ser
385					390					395					400
Ala	Lys	Thr	Leu	Lys	Asn	Arg	Pro	Cys	Leu	Ser	Pro	Lys	Leu	Pro	Thr
				405					410					415	
Pro	Gly	Ser	Ser	Asp	Pro	Leu	Ile	Gln	Pro	Ser	Ser	Pro	Ala	Val	Cys
				420					425				430		
Pro	Glu	Pro	Pro	Ser	Ser	Pro	Lys	His	Val	Ser	Ser	Val	Thr	Ser	Arg
				435					440				445		
Thr	Gly	Ser	Ser	Gly	Ala	Lys	Glu	Met	Lys	Leu	Lys	Gly	Ala	Asp	Gly
				450		455					460				
Lys	Thr	Lys	Ile	Ala	Thr	Pro	Arg	Gly	Ala	Ala	Pro	Pro	Gly	Gln	Lys
465					470					475					480
Gly	Gln	Ala	Asn	Ala	Thr	Arg	Ile	Pro	Ala	Lys	Thr	Pro	Pro	Ala	Pro
				485					490					495	
Lys	Thr	Pro	Pro	Ser	Ser	Gly	Glu	Pro	Pro	Lys	Ser	Gly	Asp	Arg	Ser
				500					505				510		
Gly	Tyr	Ser	Ser	Pro	Gly	Ser	Pro	Gly	Thr	Pro	Gly	Ser	Arg	Ser	Arg
				515			520					525			
Thr	Pro	Ser	Leu	Pro	Thr	Pro	Pro	Thr	Arg	Glu	Pro	Lys	Lys	Val	Ala
				530		535					540				
Val	Val	Arg	Thr	Pro	Pro	Lys	Ser	Pro	Ser	Ser	Ala	Lys	Ser	Arg	Leu
545					550					555					560
Gln	Thr	Ala	Pro	Val	Pro	Met	Pro	Asp	Leu	Lys	Asn	Val	Lys	Ser	Lys
				565					570					575	
Ile	Gly	Ser	Thr	Glu	Asn	Leu	Lys	His	Gln	Pro	Gly	Gly	Gly	Lys	Val
				580					585				590		
Gln	Ile	Ile	Asn	Lys	Lys	Leu	Asp	Leu	Ser	Asn	Val	Gln	Ser	Lys	Cys
				595			600					605			
Gly	Ser	Lys	Asp	Asn	Ile	Lys	His	Val	Pro	Gly	Gly	Gly	Ser	Val	Gln
				610		615					620				
Ile	Val	Tyr	Lys	Pro	Val	Asp	Leu	Ser	Lys	Val	Thr	Ser	Lys	Cys	Gly
625					630					635					640
Ser	Leu	Gly	Asn	Ile	His	His	Lys	Pro	Gly	Gly	Gly	Gln	Val	Glu	Val
				645					650					655	
Lys	Ser	Glu	Lys												
				660											

<210> SEQ ID NO 68

-continued

<211> LENGTH: 670
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 68

```

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1          5          10          15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20          25          30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35          40          45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50          55          60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65          70          75          80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85          90          95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100         105         110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
115         120         125
Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
130         135         140
Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
145         150         155         160
Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
165         170         175
Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
180         185         190
Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
195         200         205
Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
210         215         220
Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
225         230         235         240
Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
245         250         255
Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
260         265         270
Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
275         280         285
Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
290         295         300
Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
305         310         315         320
His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
325         330         335
Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
340         345         350
Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
355         360         365
Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp

```


-continued

Asp	Ala	Lys	Ser	Thr	Pro	Thr	Ala	Glu	Asp	Val	Thr	Ala	Pro	Leu	Val
65					70					75					80
Asp	Glu	Gly	Ala	Pro	Gly	Lys	Gln	Ala	Ala	Ala	Gln	Pro	His	Thr	Glu
				85					90					95	
Ile	Pro	Glu	Gly	Thr	Thr	Ala	Glu	Glu	Ala	Gly	Ile	Gly	Asp	Thr	Pro
			100					105					110		
Ser	Leu	Glu	Asp	Glu	Ala	Ala	Gly	His	Val	Thr	Gln	Glu	Pro	Glu	Ser
		115					120					125			
Gly	Lys	Val	Val	Gln	Glu	Gly	Phe	Leu	Arg	Glu	Pro	Gly	Pro	Pro	Gly
	130					135					140				
Leu	Ser	His	Gln	Leu	Met	Ser	Gly	Met	Pro	Gly	Ala	Pro	Leu	Leu	Pro
145					150					155					160
Glu	Gly	Pro	Arg	Glu	Ala	Thr	Arg	Gln	Pro	Ser	Gly	Thr	Gly	Pro	Glu
			165						170					175	
Asp	Thr	Glu	Gly	Gly	Arg	His	Ala	Pro	Glu	Leu	Leu	Lys	His	Gln	Leu
			180					185					190		
Leu	Gly	Asp	Leu	His	Gln	Glu	Gly	Pro	Pro	Leu	Lys	Gly	Ala	Gly	Gly
		195					200					205			
Lys	Glu	Arg	Pro	Gly	Ser	Lys	Glu	Glu	Val	Asp	Glu	Asp	Arg	Asp	Val
	210					215					220				
Asp	Glu	Ser	Ser	Pro	Gln	Asp	Ser	Pro	Pro	Ser	Lys	Ala	Ser	Pro	Ala
225					230					235					240
Gln	Asp	Gly	Arg	Pro	Pro	Gln	Thr	Ala	Ala	Arg	Glu	Ala	Thr	Ser	Ile
			245						250					255	
Pro	Gly	Phe	Pro	Ala	Glu	Gly	Ala	Ile	Pro	Leu	Pro	Val	Asp	Phe	Leu
		260						265					270		
Ser	Lys	Val	Ser	Thr	Glu	Ile	Pro	Ala	Ser	Glu	Pro	Asp	Gly	Pro	Ser
		275					280					285			
Val	Gly	Arg	Ala	Lys	Gly	Gln	Asp	Ala	Pro	Leu	Glu	Phe	Thr	Phe	His
	290					295					300				
Val	Glu	Ile	Thr	Pro	Asn	Val	Gln	Lys	Glu	Gln	Ala	His	Ser	Glu	Glu
305					310					315					320
His	Leu	Gly	Arg	Ala	Ala	Phe	Pro	Gly	Ala	Pro	Gly	Glu	Gly	Pro	Glu
			325						330					335	
Ala	Arg	Gly	Pro	Ser	Leu	Gly	Glu	Asp	Thr	Lys	Glu	Ala	Asp	Leu	Pro
			340					345					350		
Glu	Pro	Ser	Glu	Lys	Gln	Pro	Ala	Ala	Ala	Pro	Arg	Gly	Lys	Pro	Val
		355					360					365			
Ser	Arg	Val	Pro	Gln	Leu	Lys	Ala	Arg	Met	Val	Ser	Lys	Ser	Lys	Asp
	370					375						380			
Gly	Thr	Gly	Ser	Asp	Asp	Lys	Lys	Ala	Lys	Thr	Ser	Thr	Arg	Ser	Ser
385					390					395					400
Ala	Lys	Thr	Leu	Lys	Asn	Arg	Pro	Cys	Leu	Ser	Pro	Lys	Leu	Pro	Thr
			405						410					415	
Pro	Gly	Ser	Ser	Asp	Pro	Leu	Ile	Gln	Pro	Ser	Ser	Pro	Ala	Val	Cys
			420					425					430		
Pro	Glu	Pro	Pro	Ser	Ser	Pro	Lys	His	Val	Ser	Ser	Val	Thr	Ser	Arg
		435					440					445			
Thr	Gly	Ser	Ser	Gly	Ala	Lys	Glu	Met	Lys	Leu	Lys	Gly	Ala	Asp	Gly
	450					455						460			
Lys	Thr	Lys	Ile	Ala	Thr	Pro	Arg	Gly	Ala	Ala	Pro	Pro	Gly	Gln	Lys

-continued

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400
 Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415
 Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430
 Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445
 Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460
 Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480
 Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495
 Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510
 Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525
 Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540
 Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu

-continued

Lys	Glu	Arg	Pro	Gly	Ser	Lys	Glu	Glu	Val	Asp	Glu	Asp	Arg	Asp	Val
210						215					220				
Asp	Glu	Ser	Ser	Pro	Gln	Asp	Ser	Pro	Pro	Ser	Lys	Ala	Ser	Pro	Ala
225					230					235					240
Gln	Asp	Gly	Arg	Pro	Pro	Gln	Thr	Ala	Ala	Arg	Glu	Ala	Thr	Ser	Ile
				245					250					255	
Pro	Gly	Phe	Pro	Ala	Glu	Gly	Ala	Ile	Pro	Leu	Pro	Val	Asp	Phe	Leu
			260					265					270		
Ser	Lys	Val	Ser	Thr	Glu	Ile	Pro	Ala	Ser	Glu	Pro	Asp	Gly	Pro	Ser
		275					280					285			
Val	Gly	Arg	Ala	Lys	Gly	Gln	Asp	Ala	Pro	Leu	Glu	Phe	Thr	Phe	His
	290					295					300				
Val	Glu	Ile	Thr	Pro	Asn	Val	Gln	Lys	Glu	Gln	Ala	His	Ser	Glu	Glu
305					310					315					320
His	Leu	Gly	Arg	Ala	Ala	Phe	Pro	Gly	Ala	Pro	Gly	Glu	Gly	Pro	Glu
				325					330					335	
Ala	Arg	Gly	Pro	Ser	Leu	Gly	Glu	Asp	Thr	Lys	Glu	Ala	Asp	Leu	Pro
			340					345					350		
Glu	Pro	Ser	Glu	Lys	Gln	Pro	Ala	Ala	Ala	Pro	Arg	Gly	Lys	Pro	Val
		355					360					365			
Ser	Arg	Val	Pro	Gln	Leu	Lys	Ala	Arg	Met	Val	Ser	Lys	Ser	Lys	Asp
	370					375					380				
Gly	Thr	Gly	Ser	Asp	Asp	Lys	Lys	Ala	Lys	Thr	Ser	Thr	Arg	Ser	Ser
385					390					395					400
Ala	Lys	Thr	Leu	Lys	Asn	Arg	Pro	Cys	Leu	Ser	Pro	Lys	Leu	Pro	Thr
			405					410						415	
Pro	Gly	Ser	Ser	Asp	Pro	Leu	Ile	Gln	Pro	Ser	Ser	Pro	Ala	Val	Cys
			420					425					430		
Pro	Glu	Pro	Pro	Ser	Ser	Pro	Lys	His	Val	Ser	Ser	Val	Thr	Ser	Arg
		435					440					445			
Thr	Gly	Ser	Ser	Gly	Ala	Lys	Glu	Met	Lys	Leu	Lys	Gly	Ala	Asp	Gly
	450					455					460				
Lys	Thr	Lys	Ile	Ala	Thr	Pro	Arg	Gly	Ala	Ala	Pro	Pro	Gly	Gln	Lys
465					470					475					480
Gly	Gln	Ala	Asn	Ala	Thr	Arg	Ile	Pro	Ala	Lys	Thr	Pro	Pro	Ala	Pro
				485					490					495	
Lys	Thr	Pro	Pro	Ser	Ser	Gly	Glu	Pro	Pro	Lys	Ser	Gly	Asp	Arg	Ser
			500					505					510		
Gly	Tyr	Ser	Ser	Pro	Gly	Ser	Pro	Gly	Thr	Pro	Gly	Ser	Arg	Ser	Arg
		515					520					525			
Thr	Pro	Ser	Leu	Pro	Thr	Pro	Pro	Thr	Arg	Glu	Pro	Lys	Lys	Val	Ala
	530					535					540				
Val	Val	Arg	Thr	Pro	Pro	Lys	Ser	Pro	Ser	Ser	Ala	Lys	Ser	Arg	Leu
545					550					555					560
Gln	Thr	Ala	Pro	Val	Pro	Met	Pro	Asp	Leu	Lys	Asn	Val	Lys	Ser	Lys
				565				570						575	
Ile	Gly	Ser	Thr	Glu	Asn	Leu	Lys	His	Gln	Pro	Gly	Gly	Gly	Lys	Val
			580					585					590		
Gln	Ile	Ile	Asn	Lys	Lys	Leu	Asp	Leu	Ser	Asn	Val	Gln	Ser	Lys	Cys
		595					600					605			
Gly	Ser	Lys	Asp	Asn	Ile	Lys	His	Val	Pro	Gly	Gly	Gly	Ser	Val	Gln

-continued

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400
 Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415
 Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430
 Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445
 Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460
 Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480
 Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495
 Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510
 Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525
 Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540
 Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
 545 550 555 560
 Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 565 570 575
 Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 580 585 590
 Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
 595 600 605
 Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser Val Gln
 610 615 620
 Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly
 625 630 635 640
 Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val
 645 650 655
 Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly
 660 665 670
 Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn Lys Lys Ile

-continued

His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335

Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350

Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365

Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380

Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400

Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415

Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430

Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460

Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480

Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495

Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510

Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525

Thr Pro Ser Leu Pro Thr Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540

Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
 545 550 555

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 565 570 575

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 580 585 590

Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
 595 600 605

Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser Val Gln
 610 615 620

Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly
 625 630 635 640

Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val
 645 650 655

Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly
 660 665 670

Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn Lys Lys Ile
 675 680 685

Glu Thr His Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala Lys Thr Asp
 690 695 700

His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser Gly Asp Thr
 705 710 715 720

-continued

```

<210> SEQ ID NO 74
<211> LENGTH: 730
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 74

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1          5          10          15

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20          25          30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35          40          45

Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50          55          60

Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65          70          75          80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85          90          95

Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100         105         110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
115         120         125

Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
130         135         140

Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
145         150         155         160

Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
165         170         175

Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
180         185         190

Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
195         200         205

Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
210         215         220

Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
225         230         235         240

Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
245         250         255

Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
260         265         270

Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
275         280         285

Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
290         295         300

Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
305         310         315         320

His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
325         330         335

Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
340         345         350

Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
355         360         365

```

-continued

```

Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370                               375                380

Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
385                               390                395                400

Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405                               410                415

Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420                               425                430

Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435                               440                445

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450                               455                460

Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
465                               470                475                480

Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485                               490                495

Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500                               505                510

Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515                               520                525

Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530                               535                540

Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
545                               550                555                560

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
565                               570                575

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 580                               585                590

Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
595                               600                605

Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser Val Gln
 610                               615                620

Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly
625                               630                635                640

Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val
 645                               650                655

Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly
 660                               665                670

Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn Lys Lys Ile
 675                               680                685

Glu Thr His Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala Lys Thr Asp
 690                               695                700

His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser Gly Asp Thr
705                               710                715                720

Ser Pro Arg His Leu Ser Asn Val Ser Ser
 725                               730

```

```

<210> SEQ ID NO 75
<211> LENGTH: 740
<212> TYPE: PRT
<213> ORGANISM: Human
<400> SEQUENCE: 75

```

-continued

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125
 Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140
 Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400

-continued

Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415

Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430

Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460

Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480

Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495

Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510

Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525

Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540

Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
 545 550 555 560

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 565 570 575

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 580 585 590

Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
 595 600 605

Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser Val Gln
 610 615 620

Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly
 625 630 635 640

Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val
 645 650 655

Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly
 660 665 670

Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn Lys Lys Ile
 675 680 685

Glu Thr His Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala Lys Thr Asp
 690 695 700

His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser Gly Asp Thr
 705 710 715 720

Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser Ile Asp Met
 725 730 735

Val Asp Ser Pro
 740

<210> SEQ ID NO 76
 <211> LENGTH: 750
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 76

Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
 1 5 10 15

-continued

Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
 20 25 30
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
 35 40 45
 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
 50 55 60
 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
 65 70 75 80
 Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
 85 90 95
 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
 100 105 110
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Glu Pro Glu Ser
 115 120 125
 Gly Lys Val Val Gln Glu Gly Phe Leu Arg Glu Pro Gly Pro Pro Gly
 130 135 140
 Leu Ser His Gln Leu Met Ser Gly Met Pro Gly Ala Pro Leu Leu Pro
 145 150 155 160
 Glu Gly Pro Arg Glu Ala Thr Arg Gln Pro Ser Gly Thr Gly Pro Glu
 165 170 175
 Asp Thr Glu Gly Gly Arg His Ala Pro Glu Leu Leu Lys His Gln Leu
 180 185 190
 Leu Gly Asp Leu His Gln Glu Gly Pro Pro Leu Lys Gly Ala Gly Gly
 195 200 205
 Lys Glu Arg Pro Gly Ser Lys Glu Glu Val Asp Glu Asp Arg Asp Val
 210 215 220
 Asp Glu Ser Ser Pro Gln Asp Ser Pro Pro Ser Lys Ala Ser Pro Ala
 225 230 235 240
 Gln Asp Gly Arg Pro Pro Gln Thr Ala Ala Arg Glu Ala Thr Ser Ile
 245 250 255
 Pro Gly Phe Pro Ala Glu Gly Ala Ile Pro Leu Pro Val Asp Phe Leu
 260 265 270
 Ser Lys Val Ser Thr Glu Ile Pro Ala Ser Glu Pro Asp Gly Pro Ser
 275 280 285
 Val Gly Arg Ala Lys Gly Gln Asp Ala Pro Leu Glu Phe Thr Phe His
 290 295 300
 Val Glu Ile Thr Pro Asn Val Gln Lys Glu Gln Ala His Ser Glu Glu
 305 310 315 320
 His Leu Gly Arg Ala Ala Phe Pro Gly Ala Pro Gly Glu Gly Pro Glu
 325 330 335
 Ala Arg Gly Pro Ser Leu Gly Glu Asp Thr Lys Glu Ala Asp Leu Pro
 340 345 350
 Glu Pro Ser Glu Lys Gln Pro Ala Ala Ala Pro Arg Gly Lys Pro Val
 355 360 365
 Ser Arg Val Pro Gln Leu Lys Ala Arg Met Val Ser Lys Ser Lys Asp
 370 375 380
 Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Thr Ser Thr Arg Ser Ser
 385 390 395 400
 Ala Lys Thr Leu Lys Asn Arg Pro Cys Leu Ser Pro Lys Leu Pro Thr
 405 410 415

-continued

Pro Gly Ser Ser Asp Pro Leu Ile Gln Pro Ser Ser Pro Ala Val Cys
 420 425 430

Pro Glu Pro Pro Ser Ser Pro Lys His Val Ser Ser Val Thr Ser Arg
 435 440 445

Thr Gly Ser Ser Gly Ala Lys Glu Met Lys Leu Lys Gly Ala Asp Gly
 450 455 460

Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys
 465 470 475 480

Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro
 485 490 495

Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser
 500 505 510

Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 515 520 525

Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 530 535 540

Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu
 545 550 555 560

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 565 570 575

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 580 585 590

Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
 595 600 605

Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser Val Gln
 610 615 620

Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly
 625 630 635 640

Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val
 645 650 655

Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly
 660 665 670

Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn Lys Lys Ile
 675 680 685

Glu Thr His Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala Lys Thr Asp
 690 695 700

His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser Gly Asp Thr
 705 710 715 720

Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser Ile Asp Met
 725 730 735

Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Val Ser
 740 745 750

<210> SEQ ID NO 77
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 77

Gln Leu Ala Thr Leu Ala Asp Glu Val Ser Ala Ser Leu Ala Lys Gln
 1 5 10 15

Gly Leu

-continued

<210> SEQ ID NO 78
 <211> LENGTH: 28
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 78

Thr Gly Ser Ile Asp Met Val Asp Ser Pro Gln Leu Ala Thr Leu Ala
 1 5 10 15
 Asp Glu Val Ser Ala Ser Leu Ala Lys Gln Gly Leu
 20 25

<210> SEQ ID NO 79
 <211> LENGTH: 30
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 79

Ser Ser Thr Gly Ser Ile Asp Met Val Asp Ser Pro Gln Leu Ala Thr
 1 5 10 15
 Leu Ala Asp Glu Val Ser Ala Ser Leu Ala Lys Gln Gly Leu
 20 25 30

<210> SEQ ID NO 80
 <211> LENGTH: 40
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 80

Asp Thr Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser Ile
 1 5 10 15
 Asp Met Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Val Ser
 20 25 30
 Ala Ser Leu Ala Lys Gln Gly Leu
 35 40

What is claimed is:

1. A method of monitoring or detecting a neurological condition in a patient, the method comprises:

- (a) obtaining from a patient a fluid sample from outside of a brain tissue of the patient, the fluid sample contains a circulating phagocyte; and
- (b) detecting an biomarker associated with the neurological condition in the phagocyte.

2. The method of claim 1, wherein the circulating phagocyte includes a monocyte, a macrophage, a lymphocyte, or a combination thereof.

3. The method of claim 1, wherein the phagocyte sample is obtained from blood, peripheral blood mononuclear cells (PBMCs), cerebrospinal fluid (CSF), synovial fluid, cystic fluid, lymph fluid, ascites, pleural effusion, interstitial fluid, ocular fluids, vitreal fluid, urine, the like, or a combination thereof.

4. The method of claim 1, wherein the antigen is derived from a brain source or a non-brain source.

5. The method of claim 1, wherein one or more antigens associated with the neurological condition is detected in the sample.

6. The method of claim 1, wherein the method is used in combination with a different method for detecting the neurological condition.

7. A method of monitoring or detecting multiple sclerosis (or a risk of multiple sclerosis) in a patient, the method comprises:

- (a) obtaining from the patient a fluid sample from outside of a brain tissue of the patient, the fluid sample contains a circulating phagocyte; and
- (b) detecting one or more multiple sclerosis-associated biomarkers in the phagocyte.

8. The method of claim 7, wherein at least one multiple sclerosis-associated biomarker is a protein selected from the group consisting of Tau or a fragment thereof, phosphorylated Tau or a fragment thereof, neuroglobin, valosin-containing protein, brain hexokinase, hippocalcin-1, nestin, synaptotagmin, myelin associated glycoprotein, transketolase, NS1 associated protein 1, major vault protein, synaptojanin, enolase, alpha synuclein, glial fibrillary acidic protein, S-100 proteinNeu-N, 26S proteasome subunit 9, annexin A2, annexin A3, annexin A5, annexin A6, annexin A11, ubiquitin activating enzyme ZE1, ubiquitin B precursor, vimentin, glyceraldehyde-3-phosphate dehydrogenase, 13-3-3 protein, or fragments thereof.

9. The method of claim 7, wherein the biomarker is an insoluble protein, including an insoluble Tau protein.

10. The method of claim 9, wherein the phosphorylated residue includes serine 214, serine 235, serine 262, serine 356, serine 396, serine 404, serine 413, serine 46, serine 515, serine 516, serine 519, serine 531, serine 552, serine 610, serine 622, serine 641, serine 713, serine 721, serine 726, serine 730, serine 739, threonine 181, threonine 205, threonine 470, threonine 492, threonine 498, threonine 522, threonine 529, threonine 534, threonine 548, the like, or a combination thereof.

11. The method of claim 7, wherein the antigen is derived from a brain source or a non-brain source.

12. The method of claim 7, wherein one or more antigens associated with the neurological condition is detected in the sample.

13. The method of claim 7, wherein the phagocyte sample is derived from blood, peripheral blood mononuclear cells (PBMCs), cerebrospinal fluid (CSF), a central nervous system tissue, synovial fluid, cystic fluid, lymph fluid, ascites, pleural effusion, interstitial fluid, ocular fluids, vitreal fluid, the like, or a combination thereof.

14. The method claim 4, wherein detecting the multiple sclerosis-associated antigen in the sample comprises introducing an antibody to the sample, wherein the antibody binds to the multiple sclerosis-associated antigen.

15. The method of claim 4, wherein detecting the multiple sclerosis-associated antigen comprises subjecting the sample to a western blot, an enzyme-linked immunosorbent assay

(ELISA), a lateral flow assay, an immunohistochemistry assay, a radioimmunoassay, a bioluminescent assay, a chemiluminescent assay, a mass spectrometry assay, a flow cytometry assay, a fluorescent assay, a colorimetric assay, a enzymatic assay, a ligand binding assay, or a combination thereof.

16. The method of claim 4, wherein the method is used in combination with a different method for detecting the neurological condition.

17. A method of monitoring or detecting an inflammatory condition in a patient, said method comprising:

- (a) obtaining from the patient a fluid sample from outside of a brain tissue of the patient, the fluid sample contains a circulating phagocyte; and
- (b) detecting one or more antigens in the phagocyte, wherein the antigen is associated with the inflammatory condition.

18. The method of claim 17, wherein the phagocyte sample is derived from blood, peripheral blood mononuclear cells (PBMCs), cerebrospinal fluid (CSF), a central nervous system tissue, synovial fluid, cystic fluid, lymph fluid, ascites, pleural effusion, interstitial fluid, ocular fluids, vitreal fluid, the like, or a combination thereof.

19. The method of claim 17, wherein one or more antigens associated with the neurological condition is detected in the sample.

20. The method of claim 17, wherein the method is used in combination with a different method for detecting the neurological condition.

* * * * *

专利名称(译)	通过分析循环吞噬细胞检测神经病症的方法		
公开(公告)号	US20100055722A1	公开(公告)日	2010-03-04
申请号	US12/325035	申请日	2008-11-28
[标]申请(专利权)人(译)	NAYAK RAMESHÇ WESSELHOFT MARIE		
申请(专利权)人(译)	NAYAK RAMESHÇ WESSELHOFT MARIE		
当前申请(专利权)人(译)	NAYAK RAMESHÇ WESSELHOFT MARIE		
[标]发明人	NAYAK RAMESH C WESSELHOFT MARIE		
发明人	NAYAK, RAMESH C. WESSELHOFT, MARIE		
IPC分类号	G01N33/53 C12Q1/02 C12Q1/48 C12Q1/32		
CPC分类号	G01N2800/285 G01N33/6896		
优先权	60/991594 2007-11-30 US 61/007728 2007-12-14 US 61/020820 2008-01-14 US 61/042407 2008-04-04 US		
其他公开文献	US8506933		
外部链接	Espacenet USPTO		

摘要(译)

本发明的特征在于监测或检测患者的神经或炎症状况的方法。该方法包括 (1) 从患者获得来自患者脑组织外部的流体样品，其中流体样品含有循环吞噬细胞，和 (2) 检测一种或多种生物标志物 (例如，一组生物标志物) 在吞噬细胞内，其中生物标志物与相应的神经或炎症病症相关。

1) TABLE 1

Length (# of Amino Acids)	MW (Daltons)	Amino Acid Sequence	Amino Acids	SEQ ID NO
758 AA [This is the length of the unprocessed precursor]	78,878 Da [This is the MW of the unprocessed precursor]	MAEPRQEFV MEDHAGTYGL GDRFDQGGYT MHQDQEGTD AGLKESFLQT PTEGDSSEFG SSTSDAKSTP TAEU/TAPLV DSGAPGQAA AQPTEIPEG TTAEZAGIGD TPLSEDERAG HVTQEPESGK VVQEGFLREP GPPGLSHGLM SGMPGAPLLP EGPREATROP SGTGPEDETEG GRHAPPELLKH QLLGDLHQEG PPLKAGGKKE EFGSKREVDE DRDVEDSSPQ DSPPSKASPA QGGPPQTA RESTSIPGP AKGALDPLVD FLSKVSTEIP ASEPDGPSVG RAKQDAPLE FTPHVEITFN VQKEQAHSEE HLGRAAPPGA PGEQPEARQP ELGEDTKEAD LPEPSEKQPA AAPRGKPVSR VPQLKARWVS KRKDGTSDD KKAATSTRSS ARLNHRPCL SPKLPFPGSS DPLIQSSFA VCPPEPSSPK HVSSVTRTG SSGAKEMKIK GADGKTKIAT PRGAAPPQK GQANATRIKA KTPPAKTPP SSGEPPKSGD RSGYSSNGEP GTPGSRKTP SLPTPTREP KKAIVRFPD KPSGAKSLK QIAPVMPDL KNVSKIGST ENLKHQPGG KVQIINKLD LSNVQSKCG KDNKHVPGG GSVIVYKPV DLSKVTSKCG SLGNIHHPG GGQVEVSEK LDFKDRVQSK IGSLDNITHV PGGNKKIET HLIFPERAK AKDKSEIV YSPVVSQDT SPRHLSNVSS TGSIMVDSF QATLADLEVS ASLAKOGL	1-758	1

[0042] Table 2 shows examples of some of the possible multiple sclerosis-associated biomarkers (e.g., Iau protein or a fragment thereof).